User Image Cart Icon 0 Search Image

Cardiac Glycosides

  1. … -chemical applications of liquid chromatography II. Investigations of the surface properties of chemically modified silica gels and of the adsorption of cardiac glycosides …
  2. … , stimulation of the central adrenergic structures and blockade of beta-adrenergic receptors on cardiotonic and cardiotoxic effect of cardiac glycosides
  3. … : High resolution mass spectrometry and tandem mass spectrometry analysis of the ions formed by fast atom bombardment of digoxin and related cardiac glycosides
  4. … ) propionyl)-succinimide—A heterobifunctional reagent for the synthesis of radioactive photoaffinity ligands: Synthesis of a carrier-free 125I-labeled cardiac glycoside …
  5. … a novel mechanism of cardiac glycosides in cancer therapeutics: Evaluation of: Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1α …
  6. … Concentration Measurement and Clinical Parameters in a Geriatric Population Treated for Cardiac Insufficiency Using the Nonrenal-Dependent cardiac glycoside …
  7. … formation of. BETA.-alkyl glycosides by. BETA.-galactosidase from Aspergillus oryzae and its application to the synthesis of chemically unstable cardiac glycosides.
  8. … from med-icinal plants (or derivatives of such compounds) have found application in conventional medicine. Thus, the cardiotonic cardiac glycoside sodium pump (Na …
  9. … highly purified Na+, K+-ATPase from canine renal medulla: Separation of the “holoenzyme antibody” into catalytic and cardiac glycoside receptor-specific components
  10. … in Natural Products, Modulators of Organic Anion Transporting Polypeptides from Rollinia emarginata, and Pregnane and cardiac glycosides from Asclepias spp.
  11. … injection of human neural stem cells expressing anti-cancer agent targets invasive gliomas and induces tumor regression in combination with a cardiac glycoside.
  12. … layers for controlling the quality of phytochemical preparations and plant raw materials. I. Some characteristics of the relationship of structure to cardiac glycoside …
  13. … of Ca++ in sarcoplasmic reticulum of rabbit skeletal muscle. Influence of monophasic electrical stimulation of exactly defined strength and of cardiac glycosides.
  14. … of Cardiac Output (Ballistocardiogram) and Electrocardiogram in Normal Man After the Intravenous Administration of Purified cardiac glycosides
  15. … of monovalent ion activation of the (Na+-K+)-dependent adenosine triphosphatase and a model for ion translocation and its inhibition by the cardiac glycosides
  16. … of Sodium-and Potassium-Dependent Adenosine Triphosphatase: III. Dissociation Rate Constants of Various Enzyme—cardiac glycoside Complexes Formed in the …
  17. … of the α1β1 Isoform of the Na, K-ATPase by 8-methoxycoumestrol Without Positive Inotropic Effect in Human Myocardium-Novel Aspects of cardiac glycoside …
  18. … potassium and sodium content in the erythocytes and blood plasma in rheumatic heart defects before and after treatment with cardiac glycosides and in combination …
  19. … principles in Nigella sativa and stabilize an E2P conformation of the Na, K-ATPase. Fatty acids differentially regulate cardiac glycoside interaction with the …
  20. … RECEPTORS IN THE HEART. Erland Erdmann, Medizinische Klinik I, University of Munich, D-8000 Miinchen 70, Germany. cardiac glycosides bind with high affinity …
  21. … showed the presence of steroids. Terpenoids were present in all parts of O. sanctum and O. canum than the other plants. The cardiac glycosides were present in all …
  22. … Steroids for the Inhibition of Sodium-and Potassium-Dependent Adenosine Triphosphatase: II. Association Rate Constants of Various Enzyme—cardiac glycoside …
  23. … to low concentrations of tumor necrosis factor α attenuates the positive inotropic response not only to catecholamines but also to cardiac glycosides and high calcium …
  24. … to predict drug candidates: Mapping driver dysregulated target networks onto pharmacologic data-derived drug networks identifies cardiac glycosides as the potential …
  25. … to study of solute transport across membranes using suspension cultures of mammalian cells V: Uptake and release kinetics of cardiac glycosides by burkitt lymphoma …
  26. … vitro cytotoxic effects and ultrastructural changes in myocardial (H9c2) and neuroblastoma (neuro-2a) cell lines following exposure to three different cardiac glycosides
  27. … β-adrenoblockers, angiotensin-converting enzyme inhibitors, calcium antagonists, diuretics, anticoagulants, antiagregants, cardiac glycosides, and physical exercise
  28. “Myocardial” Action and Standard Unitage (USP XIV) of cardiac glycosides.
  29. (+)-Strebloside-induced cytotoxicity in ovarian cancer cells is mediated through cardiac glycoside signaling networks
  30. (Na+, K+)-ATPase and noradrenergic regulation: Effects of cardiac glycoside treatment and noradrenergic manipulations
  31. 14, 15-beta-oxido analog of proscillaridin (HOE 040). A new cardiac glycoside with low arrhythmic activity and greater absorption ratio
  32. 151 NA/K ATPase SENSITIVITY TO cardiac glycosides IN HYPERTROPHIED GUINEA PIG LEFT VENTRICLES. I. Primot, P. Olivero, D. Charlemagne INSERM …
  33. 21. PHARMACOLOGY OF cardiac glycosides
  34. 2393681. The toxicity for cattle of bufadienolide cardiac glycosides from Bryophyllum tubiflorum flowers
  35. 23Na-NMR measurements of the sodium concentration in guinea pig erythrocytes: the effects of cardiac glycoside and asebotoxin III
  36. 2469381. cardiac glycosides of Erysimum pulchellum
  37. 3′-O-Methylevomonoside: a new cytotoxic cardiac glycoside from Thevetia ahouia A. DC (Apocynaceae)
  38. 46 cardiac glycoside RECEPTOR IN EMBRYONIC AND POST-NATAL CARDIAC CELLS. TWO KINDS OF KE
  39. 702. The cardiac glycosides of Urechites suberecta
  40. 771-4 Enhancement of Delayed Afterdepolarlzatlons (DADs) and Triggered Activity by E-4031 and Dofetilide In a cardiac glycoside Model of Cell Ca2+ Overload
  41. A cardiac glycoside HTF-1 isolated from Helleborus thibetanus Franch displays potent in vitro anti-cancer activity via caspase-9, MAPK and PI3K-Akt-mTOR pathways
  42. A case of nondigitalis cardiac glycoside toxicity
  43. A comparative dose-effect study with cardiac glycosides assessing cardiac and extracardiac responses in normal subjects.
  44. A comparison of the inhibition by cardiac glycosides of the isolated intestine from the rat and the guinea pig
  45. A comprehensive review on the chemistry and pharmacology of Corchorus species—A source of cardiac glycosides, triterpenoids, ionones, flavonoids, coumarins …
  46. A contribution on the cardiac glycoside content of Convallaria majalis L. herbage.
  47. A disorder of myocardial contractile function in acute experimental coronary failure: the submolecular mechanisms and the action of cardiac glycosides
  48. A drug screen using human iPSC-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia
  49. A dual effect of cardiac glycosides on Ca current in single cells of frog heart
  50. A dvantages and disadvantages of using cardiac glycosides for cor pulmonale by changs in cardiac muscle fibre
  51. A fluorometric method for the determination of functional (Na, K)-ATPase and cardiac glycoside receptors
  52. A high-throughput screen identifies cardiac glycosides as inhibitors of N-glycosylation synthesis and function
  53. A kinetic comparison of cardiac glycoside interactions with Na+, K+-ATPases from skeletal and cardiac muscle and from kidney
  54. A mechanism of reflexogenic bradycardia produced by cardiac glycosides
  55. A mechanism of the vagal effect of cardiac glycosides
  56. A mechanism of the vagal effect of cardiac glycosides
  57. A Method for determining the Duration of Action of the cardiac glycosides
  58. A morphological study on the myocardial fine structure and the distribution of cardiac glycoside in the myocardium of the failing heart of rabbits
  59. A multispecific uptake system for taurocholate, cardiac glycosides and cationic drugs in the liver
  60. A new cardiac glycoside from Periploca forrestii
  61. A New cardiac glycoside?
  62. A note on the optical crystallographic properties of certain of the cardiac glycosides
  63. A novel cardiac glycoside from Parepigynum funingesis
  64. A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides
  65. A novel high‐pressure liquid–liquid extraction process for downstream processing in biotechnology: Extraction of cardiac glycosides
  66. A novel LC-IDMS/MS method for the determination of the cardiac glycosides digoxin and digitoxin using caesium adducts.
  67. A novel source of the cardiac glycoside digoxin from the endophytic fungus Epicoccum nigrum: isolation, characterization, production enhancement by gamma …
  68. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic …
  69. A reaction between a deaminase and heart actin, and inhibition of the effect with cardiac glycoside
  70. A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential
  71. A simple approach to follow the metabolic degradation of cardiac glycosides in vivo
  72. A slide ruler and nomogram for calculations in cumulation kinetics of cardiac glycosides (author’s transl)
  73. A specific binding protein for cardiac glycosides exists in bovine serum
  74. A specific cardiac glycoside for cardiac failure and another for atrial fibrillation?
  75. A study on the effect of cardiac glycosides on the syneresis of myofibrils in the presence of relaxing factor
  76. Absence of effects of cardiac glycosides on cardiac myosin and a Ca++-sensitive reconstituted cardiac actomyosin
  77. Absence of gene amplification in human cell mutants resistant to cardiac glycosides
  78. Absorption of cardiac glycosides from the rat respiratory tract
  79. Absorption of orally administered cardiac glycosides in cats
  80. Absorption rate studies of orally administered cardiac glycosides in cats
  81. Absorption rates of some cardiac glycosides and portal blood flow
  82. Absorption spectra of cardiac glycosides and aglycones in sulfuric acid
  83. Abstract B11: Antibody-conjugated cardiac glycosides: Potent agents for treatment of ovarian cancer
  84. Abstract# 2834: Digoxin and other cardiac glycosides inhibit HIF-1\# 945; synthesis and block tumor growth
  85. Abstract# 4621: Novel applications of cardiac glycosides in cancer therapies: insights into their molecular mechanism of action
  86. Acaricidal effects of cardiac glycosides, azadirachtin and neem oil against the camel tick, Hyalomma dromedarii (Acari: Ixodidae)
  87. Accumulation of radioactive cardiac glycosides by various brain regions in relation to the dysrhythmogenic effect
  88. Action of cardiac glycosides on diastolic and resting length of cardiac strips
  89. Action of cardiac glycosides on the polymerization of actin
  90. Actions of cardiac glycosides on the vessels of the forearm and hand
  91. Activation of cardiac ryanodine receptors by cardiac glycosides
  92. Acute effects of cardiac glycosides on aldosterone secretion in dogs with hyperaldosteronism secondary to chronic right heart failure
  93. Acute electrophysiological effects of cardiac glycosides on sinus node function and ventricular repolarization under clinical conditions
  94. Acute stimulation of Na/K pump by cardiac glycosides in the nanomolar range
  95. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to …
  96. Adonitoxol, a new cardiac glycoside of Adonis vernalis
  97. Advances in research on anticancer effects of cardiac glycosides
  98. Advances in understanding the role of cardiac glycosides in control of sodium transport in renal tubules
  99. Affinoside B, a cardiac glycoside with a diosphenol system in the aglycone, from Anodendron affine (Anodendron. I)
  100. Age-dependent change in myocardial cardiac glycoside receptor (Na, K-pump) concentration in children.
  101. Age-dependent regulation of cardiac glycoside receptors
  102. All human Na+-K+-ATPase α-subunit isoforms have a similar affinity for cardiac glycosides
  1. Alteration of contractile response of artery strips by a potassium-free solution, cardiac glycosides and changes in stimulation frequency
  2. Alteration of potassium metabolism by cardiac glycosides in suicidal intoxications (author’s transl)
  3. Amelioration of effects of hypertension and diabetes on myocardium by cardiac glycoside
  4. Amino acid residues of the Na, K-ATPase involved in ouabain sensitivity do not bind the sugar moiety of cardiac glycosides.
  5. An approach to the action of the cardiac glycosides at a cellular level∗
  6. An Efficient One‐Pot Enzymatic Synthesis of cardiac glycosides with Varied Sugar Chain Lengths
  7. An unusual case of cardiac glycoside toxicity
  8. An unusual electrocardiographic pattern of cardiac glycoside poisoning
  9. Analysis of the relation of the positive inotropic action of cardiac glycosides to the frequency of contraction of heart muscle
  10. ANALYSIS OF THEVETOSIDE, A MIXTURE OF cardiac glycosides EXTRACTED FROM THEVETIA PERHVIANA MERR.
  11. ANENT cardiac glycosides AND GLAUCOMA
  12. Angiotensin II (Ang II) Alters the Interaction of Na, K-ATPase with the cardiac glycoside Digoxin via Multiple Sites of Phosphorylation on the α-subunit
  13. Animal experiment studies of the ocular toxicity of cardiac glycosides
  14. Anthroylouabain: a specific fluorescent probe for the cardiac glycoside receptor of the sodium-potassium ATPase
  15. Anti-proliferative activity of cardiac glycosides isolated fromStreptocaulonjuventas: the relationships to chemical structures
  16. Anti‐tumor effects of cardiac glycosides on human lung cancer cells and lung tumorspheres
  17. Antibodies of restricted heterogeneity directed against the cardiac glycoside digoxin
  18. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects
  19. Anticancer and immunogenic properties of cardiac glycosides
  20. Anticancer properties of cardiac glycosides
  21. Antidotes for acute cardenolide (cardiac glycoside) poisoning
  22. Antiproliferative cardiac glycosides from the Latex of Antiaris toxicaria
  23. Antiproliferative Effects of Nerium oleander Leaves and Its cardiac glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
  24. Antiproliferative Effects of Nerium oleander Leaves and Their cardiac glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
  25. Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers
  26. Antiviral, antibacterial and cytotoxic activities of South African plants containing cardiac glycosides
  27. Apoptosis Induction in Osteosarcoma Cells by cardiac glycosides
  28. Application of HPLC-DAD instead of the guinea-pig test for the quantitative determination of cardiac glycosides
  29. Application of MATLAB in comparison of cardiac glycosides
  30. Are cardiac glycosides advisable in the treatment of food poisoning
  31. Arrhythmias Caused by cardiac glycosides
  32. Arrhythmogenic adverse effects of cardiac glycosides are mediated by redox modification of ryanodine receptors
  33. Arrhythmogenic Adverse Effects of cardiac glycosides are Mediated by Redox Modification of Ryanodine Receptors
  34. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides
  35. ATPase for the determination of cardiac glycosides
  36. Atrial standstill in a horse with cardiac glycoside intoxication
  37. Attenuation of cardiac glycoside effects during long-term treatment
  38. Autonomic nervous system actions of cardiac glycosides
  39. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside
  40. AVAILABILITY OF cardiac glycosides FOR PHARMA-COLOGICAL RECEPTOR-SITE OF MUSCLE CELLS AND POSITIVE INOTROPIC ACTION
  41. Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute …
  42. BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin
  43. Behavior of several enzymatic activities of the rabbit heart treated with cardiac glycosides. I. Variations in the succinic dehydrogenase and cytochrome oxidase activity …
  44. Behavior of several enzymatic activities of the rabbit heart treated with cardiac glycosides. II. Variations in the succinic dehydrogenase and cytochrome oxidase activity …
  45. Behaviour of cardiac glycosides and cardenolides related to digitoxigenin on sephadex LH-20
  46. Beta-receptor blockade and myocardial effects of cardiac glycosides
  47. Bidirectional paroxysmal tachycardia: Toxicity of different cardiac glycosides
  48. Biliary and urinary excretion of five cardiac glycosides and its correlation with their physical and chemical properties
  49. Biliary excretion of cardiac glycosides
  50. Binding of cardiac glycosides by the erythrocytes of patients
  51. Binding of cardiac glycosides to isolated jejunal brush borders from rat and guinea pig and their influence on membrane phosphatase systems
  52. Binding of the cardiac glycoside ouabain to intact cells
  53. Binding properties and biological effects of oxidized-ouabain on cultured neonatal-rat cardiac myocytes: Implications on the mechanism of action of the digitalis …
  54. Bioavailability of cardiac glycosides
  55. Biochemical and cross-resistance studies with HeLa cell mutants resistant to cardiac glycoside SC4453. Regulation of the resistant form of Na+/K+-ATPase in the …
  56. Biochemical basis for the targeted synthesis of cardiac glycosides with selective action
  57. BIOCHEMICAL STUDIES ON MECHANISM OF THE ACTION OF cardiac glycosides
  58. Biochemistry of sterols, cardiac glycosides, brassinosteroids, phytoecdysteroids and steroid saponins
  59. Bioconversions leading to minor cardiac glycosides in Convallaria majalis
  60. Biodistribution of two 99mTc-cardiac glycosides with end glucose unit: Effect of lipophilicity on their relative myocardial accumulation
  61. Biological activities of synthetic saponins and cardiac glycosides
  62. Biosynthesis of cardiac glycosides: Nucleotide-bound 2, 6-dideoxy-3-O-methylhexoses in leaf extracts of Nerium oleander.
  63. Biosynthesis of endogenous cardiac glycosides by mammalian adrenocortical cells: three steps forward
  64. Biotransformation of cardiac glycosides by Digitalis
  65. Biotransformation of cardiac glycosides by Digitalis Cell Cultures in Airlift Reactors
  66. Biotransformation of cardiac glycosides by Immobilized Cells of Digitalis lanata1
  67. Biotransformation of cardiac glycosides by plant cell cultures
  68. Biphasic effect of cardiac glycosides on action potential duration in isolated Purkinje fibers
  69. Blockade of the positive inotropic action of norepinephrine by cardiac glycosides in the dog during hypothermia
  70. Blood electrolyte changes in the heart-lung preparation with special reference to the effects of cardiac glycosides
  71. Bowiea volubilis Harv. ex Hook.f. (Sea Onion): In Vitro Culture and the Production of cardiac glycosides
  72. C14-Labeled cardiac glycosides
  73. Calcium-dependent depolarizations and contractions in ventricular myocardial fibers: effects of adrenaline and cardiac glycosides.
  74. Callus culture and in vitro biosynthesis of cardiac glycosides
  75. Callus culture and in vitro biosynthesis of cardiac glycosides from Calotropis gigantea (L.) Ait
  76. CAMKII Mediates cardiac glycoside Toxicity
  77. Cardenolide analogues. 10—Characterization of cardiac glycosides by chemical ionization mass spectrometry
  78. Cardenolide analogues. 11. Improved method for the use of Fétizon’s reagent in the synthesis of cardiac glycosides.
  79. Cardiac activity of newer digitalis glycosides and aglycones
  80. Cardiac arrhythmias, electrolyte abnormalities and serum cardiac glycoside concentrations in yellow oleander (Cascabela thevetia) poisoning–a prospective …
  81. Cardiac effects and glycoside concentrations in serum and urine after oral administration of beta-methy-digoxin to healthy individuals (author’s transl)
  82. Cardiac effects of six actodigin (AY-22,241)-related semisynthetic glycosides
  83. cardiac glycoside Activities Link Na+/K+ ATPase Ion-Transport to Breast Cancer Cell Migration via Correlative SAR
  84. cardiac glycoside and β-adrenergic blocker facilitate resuscitation from bupivacaine cardiotoxicity
  85. cardiac glycoside binding sites in cultured heart muscle cells
  86. cardiac glycoside binding to the Na K-ATPase in the intact myocardial cell: Electrophysiological measurement of chemical kinetics
  87. cardiac glycoside bufalin blocks cancer cell growth by inhibition of Aurora A and Aurora B activation via PI3K-Akt pathway
  88. cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition
  89. cardiac glycoside Chronotropic and Arrhythmogenic Effects in Sinoatrial Nodal Pacemaker Cells (SANC) Occur Along a Continuum of Electrochemical …
  90. cardiac glycoside composition in the leaves of Digitalis schischkinii
  91. cardiac glycoside Compound Isolated from Helleborus thibetanus Franch Displays Potent Toxicity against HeLa Cervical Carcinoma Cells through ROS …
  92. cardiac glycoside Constituents of Streblus asper with Potential Antineoplastic Activity
  93. cardiac glycoside digitoxin and its monosaccharide analogue MonoD inhibit NFκB to induce apoptotic cell death in ER+ MCF7 and triple-negative MDAMB-468 breast …
  94. cardiac glycoside downregulates NHE3 activity and
  95. cardiac glycoside downregulates NHE3 activity and expression in LLC-PK1 cells
  96. cardiac glycoside drugs
  97. cardiac glycoside effects on rat and guinea pig phospholipids.
  98. cardiac glycoside effects on rat skeletal muscle potentials and electrolytes
  99. cardiac glycoside glucoevatromonoside induces cancer type-specific cell death
  100. cardiac glycoside inhibits IL‐8‐induced biological responses by downregulating IL‐8 receptors through altering membrane fluidity
  101. cardiac glycoside interaction with solubilized myocardial sodium-and potassium-dependent adenosine triphosphatase
  102. cardiac glycoside interconversions at the subcellular level in Convallaria majailis
  103. cardiac glycoside intoxication
  104. cardiac glycoside ouabain induces activation of ATF-1 and StAR expression by interacting with the α4 isoform of the sodium pump in Sertoli cells
  105. cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2
  106. cardiac glycoside plants self-poisoning
  107. cardiac glycoside poisoning following suicidal ingestion of Cerbera manghas
  108. cardiac glycoside poisoning in sheep caused by Urginea physodes (Jacq.) Bak. and the isolated physodine A
  109. cardiac glycoside poisoning involved in deaths from traditional medicines
  110. cardiac glycoside receptor in potassium depletion.
  111. cardiac glycoside receptor,(Na++ K+) ATPase activity and force of contraction in rat heart
  112. cardiac glycoside Receptors and Positive Inotropy Evidence for more than one receptor?
  113. cardiac glycoside receptors in clinical and experimental states of chronic renal failure.
  114. cardiac glycoside receptors in cultured heart cells I
  115. cardiac glycoside receptors in cultured heart cells—II: Characterization of a high affinity and a low affinity binding site in heart muscle cells from neonatal rats
  116. cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation
  117. cardiac glycoside tolerance in cultured chicken heart muscle cells—a dose-dependent phenomenon
  118. cardiac glycoside toxicity in small laboratory animals
  119. cardiac glycoside toxicity resulting from cough linctus abuse
  120. cardiac glycoside toxicity: an unusual manifestation of drug addiction
  121. cardiac glycoside toxicity: more than 200 years and counting
  122. cardiac glycoside-induced cell death and Rho/Rho kinase pathway: Implication of different regulation in cancer cell lines
  123. cardiac glycoside-induced elevation of intracellular Na+ ion concentration in human erythrocytes studied by 23Na NMR spectroscopy: relationship between inotropy …
  124. cardiac glycoside-induced elevation of intracellular Na+ ion concentration in human erythrocytes studied by 23Na NMR spectroscopy. Relationship between inotropy …
  125. cardiac glycoside-like effects of a bufadienolide extracted from Kalanchoe daigremontiana
  126. cardiac glycoside-like structure and function of 5. beta., 14. beta.-pregnanes
  127. cardiac glycoside/aglycones inhibit HIV-1 gene expression by a mechanism requiring MEK1/2-ERK1/2 signaling
  128. cardiac glycosides
  129. cardiac glycosides
  130. cardiac glycosides
  131. cardiac glycosides
  132. cardiac glycosides
  133. cardiac glycosides
  134. cardiac glycosides
  135. cardiac glycosides
  136. cardiac glycosides
  137. cardiac glycosides (cardenolides) in species of Asclepias (Asclepiadaceae)
  138. cardiac glycosides (heart poisons) in the polka-dot moth Syntomeida epilais Walk.(Ctenuchidae: Lep.) with some observations on the toxic qualities of Amata …
  139. cardiac glycosides & Other Drugs Used In Congestive Heart Failure
  140. cardiac glycosides 1785–1985: Biochemistry—Pharmacology—Clinical Relevance
  141. cardiac glycosides activate the tumor suppressor and viral restriction factor promyelocytic leukemia protein (PML)
  142. cardiac glycosides affect miRNA expression profiles in renal cell carcinoma cell lines
  143. cardiac glycosides and Aglycones by Synthesis and Microbiological Conversion1a
  144. cardiac glycosides and breast cancer risk: A systematic review and meta‐analysis of observational studies
  145. cardiac glycosides and calcium antagonists in the treatment of blood circulation insufficiency
  146. cardiac glycosides and cardiomyopathy
  147. cardiac glycosides and congestive heart failure
  148. cardiac glycosides and distastefulness: some observations on the palatability spectrum of butterflies
  149. cardiac glycosides and drugs used in dysrhythmias
  150. cardiac glycosides and drugs used in dysrhythmias
  151. cardiac glycosides and drugs used in dysrhythmias
  152. cardiac glycosides and drugs used in dysrhythmias
  153. cardiac glycosides and drugs used in dysrhythmias
  154. cardiac glycosides and drugs used in dysrhythmias
  155. cardiac glycosides and drugs used in dysrhythmias
  156. cardiac glycosides and drugs used in dysrhythmias
  157. cardiac glycosides and drugs used in dysrhythmias
  158. cardiac glycosides and drugs used in dysrhythmias
  159. cardiac glycosides and drugs used in dysrhythmias
  160. cardiac glycosides and Fab Fragments: Beyond Digoxin
  161. cardiac glycosides and intracellular Na”, K”, Ca”
  162. cardiac glycosides and intracellular Na+, K+, Ca2+
  163. cardiac glycosides and metabolites–problems of recovery in tissue extracts. Separation of visible substance spots in the nanogram range (author’s transl)
  164. cardiac glycosides and oviposition by Danaus plexippus on Asclepias fruticosa in south‐east Queensland (Australia), with notes on the effect of plant nitrogen …
  165. cardiac glycosides and Oxidative Stress in Liver Cancer
  166. cardiac glycosides and pacemaker activity of the sinus node—a microelectrode study on the isolated right atrium of the rabbit
  167. cardiac glycosides and pregnanes from Adenium obesum (studies on the constituents of Adenium. I)
  168. cardiac glycosides and sodium/potassium-ATPase
  169. cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia
  170. cardiac glycosides and their metabolites levels in plasma and heart of guinea-pigs after IV administration.
  171. cardiac glycosides and thyroidal iodide transport
  172. cardiac glycosides are broad-spectrum senolytics
  173. cardiac glycosides are potent inhibitors of interferon-β gene expression
  174. cardiac glycosides as novel cancer therapeutic agents
  175. cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking
  176. cardiac glycosides as Novel Modulators of Cancer Cell Survival
  177. cardiac glycosides block cancer growth through HIF-1α-and NF-κB-mediated Plk1
  178. cardiac glycosides correct aberrant splicing of IKBKAP‐encoded mRNA in familial dysautonomia derived cells by suppressing expression of SRSF3
  179. cardiac glycosides could protect brain cells from stroke
  180. cardiac glycosides decrease influenza virus replication by inhibiting cell protein translational machinery
  181. cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived Ets factor
  182. cardiac glycosides display selective efficacy for STK11 mutant lung cancer
  183. cardiac glycosides exert anticancer effects by inducing immunogenic cell death
  184. cardiac glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
  185. cardiac glycosides for paroxysmal atrial fibrillation?
  186. cardiac glycosides form Erysimum cheiranthoides
  187. cardiac glycosides from Antiaris toxicaria with Potent Cardiotonic Activity
  188. cardiac glycosides from Cascabela thevetioides by HPLC-MS analysis
  189. cardiac glycosides from Corchorus olitorius
  190. cardiac glycosides from Cryptostegia grandiflora
  191. cardiac glycosides from Erysimum cheiranthoides
  192. cardiac glycosides from Erysimum cheiranthoides
  193. cardiac glycosides from shoot cultures of Cryptostegia grandiflora
  194. cardiac glycosides from Strophanthus kombe
  195. cardiac glycosides from the bark of Antiaris toxicaria
  196. cardiac glycosides from the Leaves of Digitalis cariensis.
  197. cardiac glycosides from the leaves of Thevetia neriifolia
  198. cardiac glycosides from the roots of Streblus asper
  199. cardiac glycosides from the Seeds of Digitalis cariensis
  200. cardiac glycosides from the Seeds of Thevetia peruviana
  201. cardiac glycosides from the seeds of Thevetia peruviana and their pro-apoptotic activity toward cancer cells
  202. cardiac glycosides from the Seeds”‘
  203. cardiac glycosides from Yellow Oleander (Thevetia peruviana) seeds
  204. cardiac glycosides I
  205. cardiac glycosides in anaesthesia
  206. cardiac glycosides in atrial fibrillation
  207. cardiac glycosides in cancer research and cancer therapy
  208. cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials
  209. cardiac glycosides in Cell Cultures of Digitalis
  210. cardiac glycosides in complex treatment of patients with heart failure and supraventricular arrhythmias
  211. cardiac glycosides in human physiology and disease: update for entomologists
  212. cardiac glycosides in medicinal plants
  213. cardiac glycosides in North American Asclepiadaceae, a basis for unpalatability in brightly coloured Hemiptera and Coleoptera
  214. cardiac glycosides in Oncopeltus fasciatus (Dallas) (Hemiptera: Lygaeidae). I. The uptake and distribution of natural cardenolides in the body
  215. cardiac glycosides in partly submerged shoots of Digitalis lanata
  216. cardiac glycosides in the defensive secretion of chrysomelid beetles: evidence for their production by the insects
  217. cardiac glycosides in the Leaves of Some F1-Hybrids of Species of Digitalis, Especially of Digitalis cariensis (ssp. lamarckii and ssp. trojana)
  218. cardiac glycosides in the Leaves of Some F1-Hybrids of Species of Digitalis, Especially of Digitalis ferruginea
  219. cardiac glycosides in the Lygaeinae (Hemiptera: Lygaeidae)
  220. cardiac glycosides in the next millennium
  221. cardiac glycosides in the oleander aphid, Aphis nerii
  222. cardiac glycosides in the treatment of cardiogenic shock
  223. cardiac glycosides in the treatment of experimental overdose with calcium-blocking agents
  224. cardiac glycosides in traditional Chinese medicine
  225. cardiac glycosides in traumatic shock
  226. cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways
  227. cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis
  228. cardiac glycosides induce resistance to tubulin-dependent anticancer drugs in androgen-independent human prostate cancer
  229. cardiac glycosides induced toxicity in human cells expressing α1-, α2-, or α3-isoforms of Na-K-ATPase
  230. cardiac glycosides induced toxicity in human cells expressing α1-, α2-, or α3-isoforms of Na-K-ATPase
  231. cardiac glycosides inhibit detubulation in amphibian skeletal muscle fibres exposed to osmotic shock
  232. cardiac glycosides inhibit LPS-induced activation of pro-inflammatory cytokines in whole blood through an NF-κB-dependent mechanism
  233. cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition
  234. cardiac glycosides inhibit proliferation and induce apoptosis of human hematological malignant cells
  235. cardiac glycosides inhibit TNF-α/NF-κB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor
  236. cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non–small cell lung cancer cells by up-regulation of death receptors 4 and 5
  237. cardiac glycosides of Beaumontia brevituba and B. Murtonii
  238. cardiac glycosides of Cheiranthus allioni. IX
  239. cardiac glycosides of Cheiranthus allioni. V
  240. cardiac glycosides of Cheiranthus allioni. VI
  241. cardiac glycosides of Cheiranthus allioni. VII
  242. cardiac glycosides of Cheiranthus allioni. X
  243. cardiac glycosides of Cheiranthus allioni. XI
  244. cardiac glycosides of Cheiranthus allioni. XIII. Glucoerycordin
  245. cardiac glycosides of Cheiranthus cheiri.
  246. cardiac glycosides of Erysimum contractum
  247. cardiac glycosides of Erysimum contractum. II
  248. cardiac glycosides of Erysimum crepidifolium
  249. cardiac glycosides of Euonymus Atropurpurea Jacq. I.: Detection, Separation, and Isolation
  250. cardiac glycosides of euonymus atropurpurea Jacq. II. A study of the structure of euatroside and euatromonoside
  251. cardiac glycosides of the leaves of Nerium odorum
  252. cardiac glycosides of the root bark of Nerium odorum
  253. cardiac glycosides of theCheiranthus allioni. XII
  254. cardiac glycosides ofAcokanthera venenata
  255. cardiac glycosides ofCheiranthus allioni
  256. cardiac glycosides ouabain and digoxin interfere with the regulation of glutamate transporter GLAST in astrocytes cultured from neonatal rat brain
  257. cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes
  258. cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform
  259. cardiac glycosides regulate endothelial tissue factor expression in culture
  260. cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells
  261. cardiac glycosides stimulate phospholipase C activity in rat pinealocytes
  262. cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1α in human glioma stem cells
  263. cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies
  264. cardiac glycosides use and the risk of lung cancer: a nested case–control study
  265. cardiac glycosides uses in heart
  266. cardiac glycosides with different effects in the heart
  267. cardiac glycosides with non-rotating steroid to sugar linkages: tools for the study of digitalis structure-activity relationships
  268. cardiac glycosides with selectivity for the α2 isoform of NaK-ATPase (974.1)
  269. cardiac glycosides, a novel treatment for neuroblastoma: efficacy and mechanism
  270. cardiac glycosides, calcium and the release of neurotransmitter from peripheral noradrenergic nerves
  271. cardiac glycosides, digoxin toxicity, and the antidote
  272. cardiac glycosides: 2. Synthesis of glucose and galactose analogs
  273. cardiac glycosides: 3. synthesis of β-D-digitoxose analogues
  274. cardiac glycosides: 5. Stereoselective syntheses of digitoxigenin α-D, β-D, α-L, and β-L-glucosides
  275. cardiac glycosides: a leap to lupus?
  276. cardiac glycosides: a physical system for their sequestration by the milkweed bug
  277. cardiac glycosides: Correlations among Na+, K+-ATPase, sodium pump and contractility in the guinea pig heart
  278. cardiac glycosides: From ancient history through Withering’s foxglove to endogeneous cardiac glycosides
  279. cardiac glycosides: From molecular targets to immunogenic cell death
  280. cardiac glycosides: Part I: Experimental Pharmacology
  281. cardiac glycosides: Part II: Pharmacokinetics and Clinical Pharmacology
  282. cardiac glycosides: Part II: Pharmacokinetics and Clinical Pharmacology
  283. cardiac glycosides: PART VI1
  284. cardiac glycosides: Prerequisites for the development of new cardiotonic compounds
  285. cardiac glycosides: regulation of force and rhythm
  286. cardiac glycosides. 1. A systematic study of digitoxigenin D-glycosides
  287. cardiac glycosides. 4. A structural and biological analysis of. beta.-D-digitoxosides,. beta.-AYD-digitoxose acetonides and their genins
  288. cardiac glycosides. 6. Gitoxigenin C16 acetates, formates, methoxycarbonates, and digitoxosides. Synthesis and Na+, K+-ATPase inhibitory activities
  289. cardiac glycosides. 7. Sugar stereochemistry and cardiac glycoside activity
  290. Cardiac uptake and binding of cardiac glycosides
  291. Cardioprotection by cardiac glycosides is Mediated by Signalosomes Acting on Mitochondrial P38-MAP Kinase to Open Mitokatp
  292. Case report/Gevalverslag Suspected cardiac glycoside poisoning in elephants (Loxodonta africana)
  293. Catalytic Tritiation of cardiac glycosides
  294. Cation and cardiac glycoside Binding Sites of the Na,K‐ATPasea
  295. Caution from using cardiac glycosides digoxin drug which have properties therapeutic index (Ti) narrow compare with the medications wide therapeutic index
  296. Cell membrane receptors for cardiac glycosides in the heart
  297. Cell specialization and cardiac glycoside formation in cell cultures of Digitalis species
  298. Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis)
  299. Cellular mechanism of action of cardiac glycosides
  300. Changes in cardiac glycoside activity produced by aminosugar addition.
  301. Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the …
  302. Changes in cellular Na+, K+, and Ca2+ contents, monovalent cation transport rate, and contractile state during washout of cardiac glycosides from cultured chick heart …
  303. Changes in the neuronal membrane potential of the mollusk Planorbarius corneus under the action of cardiac glycosides
  304. Changes of affinity and capacity of cardiac glycoside receptors
  305. Characterization of (Na++ K+)-ATPase-liposomes. III. Controlled activation and inhibition of symmetric pumps by timed asymmetric ATP, RbCl, and cardiac glycoside …
  306. Characterization of cardiac glycoside natural products as potent inhibitors of DNA double-strand break repair by a whole-cell double immunofluorescence assay
  307. Characterization of digitalis-like factors in human plasma. Interactions with NaK-ATPase and cross-reactivity with cardiac glycoside-specific antibodies.
  308. Characterization of digoxin and related cardiac glycosides by fast atom bombardment mass spectrometry
  309. Characterization of Effects of cardiac glycosides on DifferentIsoforms of Na+,K+ ATPase in Cellular Systems
  310. Characterization of phenolic compounds and cardiac glycosides from red sea squill (Urginea maritima (L.) Baker) by RP-HPLC-DAD-MSn
  311. Characterization of the cardiac glycoside and lipid profiles of Strophanthus kombé Oliv. seeds
  312. Characterization, quantitation, similarity evaluation and combination with Na+, K+-ATPase of cardiac glycosides from Streblus asper
  313. Charge movements in intact amphibian skeletal muscle fibres in the presence of cardiac glycosides
  314. Chemistry and biochemical pharmacology of cardiac glycosides-A review
  315. Chemistry, spectroscopic characteristics and biological activity of natural occurring cardiac glycosides
  316. Chick heart cells with high intracellular calcium concentration have a higher affinity for cardiac glycosides than those with low intracellular calcium concentration, as …
  317. Chromatography of cardiac glycosides
  318. Chronopharmacodynamics of delayed-action cardiac glycosides and nitrates
  319. Chronotropic effect of cardiac glycosides in cats, dogs, and rabbits
  320. Circadian sensitivity to the cardiac glycoside oleandrin is associated with diurnal intestinal P-glycoprotein expression
  321. Cleavage of cardiac glycosides in organic media
  322. Clinical efficacy of cardiac glycosides for arrhythmias
  323. Clinical experience with the cardiac glycoside Gitoformat (author’s transl)
  324. Clinical implications of differences in pharmacodynamic action of polar and nonpolar cardiac glycosides
  325. Clinical interpretation of serum concentrations of cardiac glycosides
  326. Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction
  327. Clinical studies on a new cardiac glycoside, Acetyldigitoxin
  328. Clinically relevant interactions with cardiac glycosides
  329. Comparative ability of digoxin and an aminosugar cardiac glycoside to bind to and inhibit Na+, K+-adenosine triphosphatase: effect of potassium
  330. COMPARATIVE ANALYSIS OF cardiac glycosides AND QUANTIFICATION OF PERUVOSIDE FROM THEVETIA NERIIFOLIA, JUSS FRUIT RIND …
  331. Comparative analysis of the cardiac glycosides action on the growth of the cardiac tissue explants
  332. Comparative assessment of the cardiotonic effect of new cardiac glycosides from the Far Eastern lily of the valley.
  333. Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides.
  334. Comparative studies of some semisynthetic K-strophanthins with natural cardiac glycosides
  335. Comparative studies on dialysance and renal clearance of various cardiac glycosides
  336. Comparative study of the effect of cycloartane and cardiac glycosides on various parameters of myocardial metabolism in animals
  337. Comparative study on use of angiotensin-converting enzyme inhibitors and cardiac glycosides in the treatment of cardiac insufficiency
  338. Comparative topo-optical investigation of cardiac glycoside localization
  339. Comparison of degree of susceptibility of hyperthyroid and euthyroid animals to cardiac glycoside‐induced arrhythmias
  340. Comparison of the cardiac effects of ASI-222 HCl, an aminosugar cardiac glycoside, and digoxin.
  341. Comparison of the effect of cardiac glycosides in Periplocae Cortex on isolated heart in rats
  342. Comparison of the effects of aminosugar cardiac glycosides with ouabain and digoxin on Na+, K+-adenosine triphosphatase and cardiac contractile force.
  343. Comparison of the effects of β-palmitoyl lysolecithin and cardiac glycosides in two mammalian tissues
  344. Comparison of the inotropic potencies of some synthetic and naturally occurring cardiac glycosides using isolated left atrium of guinea pig.
  345. Compound library screening identified cardiac glycoside digitoxin as an effective growth inhibitor of gefitinib-resistant non-small cell lung cancer via downregulation of …
  346. Comprehensive transcriptome analysis reveals novel genes involved in cardiac glycoside biosynthesis and mlncRNAs associated with secondary metabolism …
  347. Concentration of cardiac glycosides in the heart and brain (author’s transl)
  348. Concepts for toxicokinetic-toxicodynamic modelling in clinical toxicology: application to acute cardiac glycoside intoxications
  349. Concerning the Contractile Proteins and cardiac glycosides
  350. Concomitant drug use among patients on cardiac glycosides
  351. Concomitant use of policosanol and cardiac glycosides in older patients
  352. Conformational factors in cardiac glycoside activity
  353. Conformations of the sugars found in cardiac glycosides
  354. Contraction dependency of the positive inotropic action of cardiac glycosides
  355. Contrasting effects of cardiac glycosides on cisplatin-and etoposide-induced cell death
  356. Contribution of clinical pharmacology to a rational use of cardiac glycosides in Czechoslovakia.
  357. Contribution to the biochemical characterization of cardiac glycosides concerning their influence on ATP-ases.
  358. Convallatoxin, the active cardiac glycoside of lily of the valley, minimally affects the ADVIA Centaur digoxin assay
  359. Convergent adaptive evolution–how insects master the challenge of cardiac glycoside‐containing host plants
  360. Correlation between the inhibitory effects of basic drugs on the uptake of cardiac glycosides and taurocholate by isolated rat hepatocytes
  361. Correlation between the molecular structure of cardiac glycosides, steroid hormones and carbohydrates and their retention in high-performance liquid …
  362. Correlation between the retention of cardiac glycosides in reversed-phase high-performance liquid chromatography a diphenylsilyl stationary phase, the structure of …
  363. Correlation study on chemical constitutes of cardiac glycosides in Taxillus chinensis and its Nerium indicum host by UPLC-Q-TOF-MS/MS
  364. Cross-resistance and biochemical characteristics of second-step mutants of HeLa cells resistant to cardiac glycosides
  365. Cross-resistance and biochemical studies with two classes of HeLa cell mutants resistant to cardiac glycosides. The unusual behavior of cardenolide SC4453.
  366. Current status of cardiac glycoside drug interactions.
  367. Cytochemical demonstration of the molecular forms of cardiac glycosides in the hart muscle
  368. Cytotoxic and non-cytotoxic cardiac glycosides isolated from the combined flowers, leaves, and twigs of Streblus asper
  369. Cytotoxic cardiac glycoside Constituents of Vallaris glabra Leaves
  370. Cytotoxic cardiac glycoside from the Parasitic Plant Cuscuta reflexa
  371. Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria
  372. Cytotoxic cardiac glycosides and Other Compounds from Asclepias syriaca
  373. Cytotoxic cardiac glycosides from the fruit (pods) of Adenium obesum (Forssk.) Roem. & Schult
  374. Cytotoxic cardiac glycosides from the roots of Streptocaulon juventas
  375. Cytotoxic cardiac glycosides from the roots of Streptocaulon juventas
  376. Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs
  377. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells
  378. DATA TO THE cardiac glycoside CONTENT OF ADONIS VERNALIS L., IN HUNGARY
  379. Deleterious synergism of a cardiac glycoside and sodium diatrizoate.
  380. Delivery of acetylthevetin B, an antitumor cardiac glycoside, using polymeric micelles for enhanced therapeutic efficacy against lung cancer cells
  381. Demonstration and characterization of two classes of cardiac glycoside binding sites to rat heart membrane preparations using quantitative computer modeling
  382. Design and synthesis of biotinylated cardiac glycosides for probing Nur77 protein inducting pathway
  383. Detection of poisoning by plant-origin cardiac glycoside with the Abbott TDx analyzer.
  384. Determination of cardiac glycosides and total phenols in different generations of Securigera securidaca suspension culture
  385. Determination of cardiac glycosides by adsorptive stripping voltammetry
  386. DETERMINATION OF cardiac glycosides BY SINGLE SWEEP POLAROGRAPHY
  387. Determination of cardiac glycosides in digitoxin tablets and deslanoside injections by micro-HPLC
  388. Determination of cardiac glycosides in Scilla bifolia (Liliaceae) by two different analytical techniques: Thin Layer Chromatography (TLC) and High Performance …
  389. Determination of the cardiac glycosides digoxin and digitoxin by liquid chromatography combined with isotope-dilution mass spectrometry (LC-IDMS)–a candidate …
  390. Determination of the therapeutic, irregularity, and lethal doses of cardiac glycosides in the heart-lung preparation of the dog
  391. Detrimental effects of latex and cardiac glycosides on survival and growth of first‐instar monarch butterfly larvae Danaus plexippus feeding on the sandhill milkweed …
  392. Development of a specific assay for cardiac glycoside-like compounds based on cross-resistance of human cell mutants
  393. Differences in color vision deficiencies induced by various cardiac glycosides.
  394. Different cell growth inhibition effects of cardiac glycosides on lung cancer cell lines A549 and H1975
  395. Different patterns of autonomic nerve activity produced by a polar vs. a neutral cardiac glycoside
  396. Differential diagnosis of supraventricular rhythm disorders and the tactics in the treatment with cardiac glycosides
  397. Differential photoaffinity labeling of catalytic subunits of NaK-ATPase with carrier-free/sup 125/I-cardiac glycosides
  398. Differential species sensitivity to the inhibitory effect of cardiac glycosides on 3H-1-noradrenaline accumulation by tissue slices.
  399. Digitalis (cardiac glycoside) poisoning
  400. Digitalis and strophanthus—cardiac glycosides
  401. Digitalis Therapy: A Reappraisal of Digitalis and cardiac glycosides.
  402. Digitalis-like pregnanes. Cardiac and renal effects of a glycoside of 14~-hydr~ x~ progesterone’
  403. Digitalis-like pregnanes. Cardiac and renal effects of a glycoside of 14β-hydroxyprogesterone
  404. Digoxin and other cardiac glycosides
  405. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
  406. Digoxin Treatment and Congestive Heart Failure in Light of Human Cardiac and Skeletal Muscle Digitalis Glycoside Receptor Studies
  407. Digoxin-like immunoreactivity, endogeneous cardiac glycoside-like factors (s) and natriuretic hormone
  408. Diltiazem attenuates the inotropic and peripheral vascular effects of cardiac glycosides
  409. Discovery of steroid glycosides with selective inotropic action using Na+/K+-ATPase isoforms expressed in’receptor blasts’. Selective inhibition of a1-isoform of Na+/K+ …
  410. Disease-related alterations in cardiac glycoside disposition
  411. Dissociation of contractile effect and binding and inhibition of Na+-K+-adenosine triphosphatase by cardiac glycosides in rabbit myometrium
  412. Distribution of cardiac glycosides in heart and brain of dogs and their affinity to the (Na++K+)-ATPase
  413. DNA extraction of plant species containing cardiac glycosides commonly found in Thailand
  414. Do cardiac glycosides affect platelet function? A flow cytometric study in healthy volunteers.
  415. Dog to cardiac glycoside and to Tachycardia
  416. Dose–response effects of cardiac glycosides on pooling and systemic and pulmonary hemodynamics
  417. Drug interactions with cardiac glycosides: evaluation of a possible digoxin-ethmozine pharmacokinetic interaction.
  418. Drugs Acting on Cardiovascular System: cardiac glycosides and inotropic agents
  419. Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450
  420. Editorial note Calcium, caffeine, cardiac glycosides, and cardiac contractile function
  421. Effect and binding of cardiac glycoside in intact and ischemic heart coronary circulation
  422. Effect of a cardiac glycoside (Cedilanid) on the sodium and potassium balance of the human heart
  423. Effect of a cardiac glycoside on the contraction and the energy-rich phosphate content of the heart poisoned with dinitrophenol
  424. Effect of a lowered catalase level on actions of cardiac glycosides
  425. Effect of age and cardiac glycosides on the activity of adenosine triphosphatase (ATPase)(EC 3.6. 1.3) of red cell ghost membranes
  426. Effect of cardiac glycosides and anabolic preparations on the indices of the blood oxygen balance and carbohydrate metabolism in ischemic heart disease patients in …
  427. Effect of cardiac glycosides and inorganic ions on binding of serotonin by platelets
  428. Effect of cardiac glycosides and sodium ethacrynate on transepithelial sodium transport inin vivo micropuncture experiments and on isolated plasma membrane Na− K …
  429. Effect of cardiac glycosides from Nerium indicum on feeding rate, digestive enzymes activity and ultrastructural alterations of hepatopancreas in Pomacea canaliculata
  430. Effect of cardiac glycosides on action potential characteristics and contractility in cat ventricular myocytes: role of calcium overload
  431. Effect of cardiac glycosides on active Na-K-transport
  432. Effect of cardiac glycosides on blood volume of the dog
  433. Effect of cardiac glycosides on human cerebrospinal-fluid production
  434. Effect of cardiac glycosides on Interaction of Ca++ with Mitochondria
  435. Effect of cardiac glycosides on isoprenaline-induced heart changes
  436. Effect of cardiac glycosides on myocardial contractile proteins
  437. Effect of cardiac glycosides on neuromuscular transmission
  438. Effect of cardiac glycosides on the calcium ion binding by biomembrane lipids
  439. Effect of cardiac glycosides on the coronaries: physiologic and morphologic studies in the dog heart.
  440. Effect of cardiac glycosides on the release of adenylate kinase into cerebrospinal fluid of patients with cerebral arteriosclerosis
  441. Effect of cardiac glycosides on whole body potassium concentration in circulatory insufficiency
  442. Effect of coronary artery dilating agents and cardiac glycosides on myocardial blood flow in acute radiation sickness.[Cats]
  443. Effect of dietary cardiac glycosides on blood pressure regulation in rats
  444. EFFECT OF DIFFRENT FACTOR ON cardiac glycoside CONTENT IN DIGIT ALIS PURPUREA LEAVES IN VITRO CULTURE [J]
  445. EFFECT OF DIFFRENT FACTOR ON cardiac glycoside CONTENT IN DIGITA $ YS PURPUREA LEAVES IN VITRO CULTURE
  446. Effect of digoxin and amino sugar cardiac glycoside (ASI-222) on plasma antidiuretic hormone activity.
  447. Effect of gross cardiac glycoside content of seeds of common milkweed,Asclepias syriaca, on cardiac glycoside uptake by the milkweed bugOncopeltus fasciatus
  448. Effect of intravenous cardiac glycosides on the aqueous humour dynamics of the cat.
  449. EFFECT OF INTRAVENOUS cardiac glycosides ON THE AQUEOUS HUMOUR DYNAMICSOF THE CAT* t
  450. Effect of irradiation by gamma rays and the use of benzyl adenine to increase the production of cardiac glycoside compounds from Digitalis lanata in vitro
  451. Effect of light and passage on cardiac glycoside production on cultured cell of Digitalis nervosa Steud & Hochst
  452. Effect of methyluracil on the sensitivity of animals to cardiac glycosides and on the coronary blood flow
  453. Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides
  454. Effect of praziquantel on the cardiotonic action of cardiac glycosides.
  455. Effect of some Pteridine compounds on the Na++ K+)-ATPase and on the cardiac glycoside receptor of human heart).
  456. Effect of the cardiac glycoside, digoxin, on neuronal viability, serotonin production and brain development in the embryo
  457. Effect of Trace Elements on cardiac glycosides Accumulation in Digitalis grandiflora
  458. Effect of transient vagal cold blockade upon reflex actions of a polar and nonpolar cardiac glycoside.
  459. Effect of treatment with cardiac glycosides and biologically active substances on the state of the lesser circulation according to the electrokymographic data
  460. Effect of two cardiac glycosides, digitoxin and digoxin on blood lipids.
  461. Effect of various cardiac glycosides on central hemodynamics after operations on the abdominal organs
  462. Effective concentration and dosage for cardiac glycosides
  463. Effectiveness of cardiac glycosides in human myocardium with and without” downregulated” beta-adrenoceptors.
  464. Effects of a cardiac glycoside in combination with propranolol on the ischemic heart of conscious dogs.
  465. Effects of a cardiac glycoside on regional function, blood flow, and electrograms in conscious dogs with myocardial ischemia.
  466. Effects of adding digitoxigenin and gitoxigenin to the nutrient medium on cardiac glycosides production from digitalis purpurea (Var. Excelsior Mixed) by using tissue …
  467. Effects of AL 107, a novel semisynthetic cardiac glycoside, on the cardiovascular system in anaesthetized beagle dogs with pentobarbital-induced cardiac …
  468. Effects of basic drugs on the hepatic transport of cardiac glycosides in rats
  469. Effects of cardiac depression and of anesthesia on the myocardial action of a cardiac glycoside
  470. Effects of cardiac glycoside from Nerium oleander on juvenile Carassius auratus.
  471. Effects of cardiac glycosides at the cellular level
  472. Effects of cardiac glycosides from Nerium indicum on Juvenile Carassius auratus
  473. Effects of cardiac glycosides injected into the atrioventricular node artery of the dog
  474. Effects of cardiac glycosides on 24‐h ambulatory blood pressure in healthy volunteers and patients with heart failure
  475. Effects of cardiac glycosides on atrial contractile dysfunction after short-term atrial fibrillation
  476. Effects of cardiac glycosides on atrial fibrillation
  477. Effects of cardiac glycosides on autonomic nervous system and endocrine glands
  478. Effects of cardiac glycosides on Central Nervous System
  479. Effects of cardiac glycosides on electrical activity in the isolated retina of the frog
  480. Effects of cardiac glycosides on excitation‐contraction coupling in frog skeletal muscle fibres.
  481. Effects of cardiac glycosides on kidneys
  482. Effects of cardiac glycosides on myocardial function and energetics in conscious dogs
  483. Effects of cardiac glycosides on myofibrils
  484. Effects of cardiac glycosides on Na+, K+-ATPase
  485. Effects of cardiac glycosides on renal adenosine triphosphatase activity and Na+ reabsorption in dogs
  486. Effects of cardiac glycosides on renal tubular transport of calcium, magnesium, inorganic phosphate, and glucose in the dog
  487. Effects of cardiac glycosides on skeletal muscle
  488. Effects of cardiac glycosides on sodium pump expression and function in LLC-PK1 and MDCK cells
  489. Effects of cardiac glycosides on spontaneous efferent activity in vagus and sympathetic nerves of cats
  490. Effects of cardiac glycosides on the abnormal pulmonary circulation of the dog
  491. Effects of cardiac glycosides on the composition of whole-mixed human saliva
  492. Effects of cardiac glycosides on the Failing and Nonfailing Heart
  493. Effects of cardiac glycosides on vascular system
  494. Effects of cardiac glycosides upon the electrical activity of single ventricular fibers of the frog heart, and their relation to the digitalis effect of the electrocardiogram
  495. Effects of chronic heart failure on the inotropic response of the right ventricle of the conscious dog to a cardiac glycoside and to tachycardia
  496. Effects of digitoxigenin, digoxigenin, and various cardiac glycosides on cardenolide accumulation in shoot cultures of Digitalis lanata
  497. EFFECTS OF ERYSIUM CHEIRANTHOIDES L TOTAL cardiac glycosides ON PHYSIOLOGICAL PROPERTIES OF GUINEA PIG LEFT ATRIA
  498. Effects of ethacrynic acid and cardiac glycosides upon a membrane adenosinetriphosphatase of renal cortex
  499. Effects of K+ on the interaction between cardiac glycosides and Na, K-ATPase
  500. Effects of quinidine on the cardiac-glycoside sensitivity of guinea-pig and rat heart.
  501. Effects of Specific 3-H-Ouabain Binding to the cardiac glycoside Receptor on (Na++K+)-ATPase Activity and on Force of Contraction in Rat Heart
  502. Effects of the cardiac glycosides on the Ca++ uptake of cardiac sarcoplasmic reticulum
  503. Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells.
  504. Effects of Two Rapid Acting cardiac glycosides on Dog’s Heart‐Lung Preparation
  505. Effects on sheep of the milkweeds Asclepias eriocarpa and A. labriformis and of cardiac glycoside-containing derivative material
  506. Elaeodendroside A: a novel cytotoxic cardiac glycoside from Elaeodendron glaucum
  507. Electrolyte and water content of the ventricular musculature of the heart-lung preparation with special reference to the effects of cardiac glycosides
  508. Electrolyte Effect of cardiac glycosides on Dog’s Heart‐Lung Preparation
  509. Electron microscopic autoradiographic study of heart muscle calcium in experimental cardiac glycoside poisoning.
  510. Electronic supplementary materialIdentification of a Na+/K+-ATPase inhibition-independent proarrhythmic ionic mechanisms of cardiac glycosides.
  511. Electrophysiological effects of cardiac glycosides
  512. Electrophysiological studies of some semisynthetic cardiac glycoside derivatives in isolated papillary muscle of the guinea-pig.
  513. Elimination of cardiac glycosides through hemofiltration
  514. Elimination of undifferentiated human embryonic stem cells by cardiac glycosides
  515. Elucidating the Mechanism of Antimigratory Activity of cardiac glycosides
  516. Embryogenesis, plant regeneration and cardiac glycoside determination in Digitalis ferruginea subsp. ferruginea L
  517. Endogenous and exogenous cardiac glycosides and their mechanisms of action
  518. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth
  519. Endogenous cardiac glycoside-like substances in newborns, adults, pregnant women and patients with hypertension or renal insufficiency.
  520. Endogenous cardiac glycosides
  521. Endogenous cardiac glycosides, a new class of steroid hormones
  522. Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer
  523. Endogenous digitalis-like substances and cardiac glycosides: facts and hypotheses
  524. Endogenous factors with immunological and biological activity similar to cardiac glycosides: Biochemical and pathophysiological implications
  525. Endogenous substances with immunological and biological activity similar to cardiac glycosides: Their possible role in the regulation of electrolytes and fluids in …
  526. Enhanced adenosine inhibition of platelet aggregation in the presence of cardiac glycosides
  527. Enhanced sensitivity of the failing human myocardium to cardiac glycosides and Na+-channel activators
  528. Enhanced sympathetic activity as a mechanism for cardiac glycoside toxicity in hypomagnesemia
  529. Enhancement of Bupivacaine Cardiotoxicity with cardiac glycosides and $ bT-Adrenergic Blockers: A Case Report
  530. Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization
  531. Enrichment of total cardiac glycoside from Semen Descuraniae by macroporous adsorption resin
  532. Enzymatic determination of cardiac glycosides
  533. Enzymatic Determination of Total cardiac glycosides in Plant Extracts
  534. Enzymic formation of β-alkyl glycosides by β-galactosidase from Aspergillus oryzae and its application to the synthesis of chemically unstable cardiac glycosides
  535. Enzymic synthesis of chemically unstable cardiac glycosides by β-galactosidase from Aspergillus oryzae
  536. Erychrosol—A new type of cardiac glycoside
  537. Erysimum cheiranthoides, an ecological research system with potential as a genetic and genomic model for studying cardiac glycoside biosynthesis
  538. erythrocyte, determined by 23’Na NMR. KEYWORDS cardiac glycoside; 23Na NMR spectrometry; proscillaridin; inotropy speed
  539. Estimating the dose of a cardiac glycoside for human subjects
  540. Estimation of tannin, saponin, oxalate, cyanogenic and cardiac glycosides in Garsinia kola
  541. Estrogenic action of cardiac glycosides. Clinical and animal experiment studies
  542. Evaluating the cancer therapeutic potential of cardiac glycosides
  543. Evaluation of cardiac glycosides in isolated heart preparations other than papillary muscle
  544. Evaluation of different methods for determining serum concentrations of cardiac glycosides
  545. Evaluation of positive and negative ion fast atom bombardment mass spectrometry for structural investigations on cardenolide‐type cardiac glycosides
  546. Evaluation of the clinical effect of treatment with cardiac glycosides under conditions of ambulatory observation
  547. Evaluation of the retention of cardiac glycosides and steroid hormones in reversed-phase liquid chromatography and their biological activity according to the …
  548. Evidence for pharmacodynamic differences between cardiac glycosides of different polarities
  549. Evidence for two kinetically and functionally different types of cardiac glycoside receptors in the heart
  550. Evolution of adaptations to cardiac glycosides in the hemipteran subfamily Lygaeinae
  551. Ex vivo activity of cardiac glycosides in acute leukaemia
  552. Experimental investigation of the effect of cardiac glycosides on the ischemic coronary circulation.
  553. Experimental results relating to the metabolism of the cardiac glycosides
  554. Experimental studies on excitability of the auricle with reference to the action of vagus nerves and cardiac glycoside
  555. Experimental Studies on Myocardial Contractility with Special Reference to the cardiac glycoside, Myocardial Electrolyte and Myocardial Catecholamine
  556. Exploration of the Micro-lecture Design of Pharmacology Based on the Sample of Positive Inotropic Effect and Mechanism of cardiac glycosides
  557. Explorations of Sodium-Potassium Adenosine Triphosphatase, Na+ K+ ATPase, and the Inhibitory cardiac glycoside, Ouabain
  558. Extracardiac effects of cardiac glycosides
  559. Extraction and chromatographic purification of digitalis cardiac glycosides and their binding to plant pigments
  560. Extraction of 137Cs by alcohol-water solvents from plants containing cardiac glycosides
  561. Extraction of Cs-137 by alcohol-water solvents from plants containing cardiac glycosides
  562. Facilitation of transmitter action on catecholamine output by cardiac glycoside in perfused adrenal gland of guinea‐pig.
  563. FACTORS AND AGENTS THAT INFLUENCE cardiac glycoside‐Na+, K+‐ATPase INTERACTION*
  564. Fatal cardiac glycoside poisoning due to mistaking foxglove for comfrey
  565. First-line treatment of cardiac insufficiency: digitalis glycosides, diuretics, vasodilator agents or new cardiotonic agents?
  566. Fluoresceinyl‐Ethylenediamine‐Ouabain Detects an Acidic Environment in the cardiac glycoside binding Site of Na+/K+‐ATPase
  567. Fluorescence study on cardiac glycoside binding to the Na, K‐pump Ouabain binding is associated with movement of electrical charge
  568. From Na+/K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment
  569. Further studies on relationship between activity and constitution in the cardiac glycoside series.
  570. Gas-chromatographic analysis of cardiac glycosides and related compounds
  571. Gel chromatography and gel electrophoresis of cardiac glycoside‐Na, K‐ATPase complexes in sodium dodecyl sulfate: A caution
  572. Ghalakinoside, a cytotoxic cardiac glycoside from Pergularia tomentosa
  573. Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency
  574. Growth inhibitory effect of cardiac glycosides and aglycones on neoplastic cells
  575. GSH responsive nanomedicines self-assembled from small molecule prodrug alleviate the toxicity of cardiac glycosides as potent cancer drugs
  576. Haemodynamic effects of prenaterol and cardiac glycosides in patients with recent myocardial infarction
  577. Heart lymph: electrolyte composition and changes induced by cardiac glycosides
  578. Heart poisons (cardiac glycosides) in the lygaeid bugs Caenocoris nerii and Spilostethus pandurus
  579. Hemodynamic effects of cardiac glycosides on normal human subjects during rest and exercise
  580. Hemodynamic examinations concerning the effects of cardiac glycosides in hypertrophic obstructive cardiomyopathy (HOCM)
  581. Herbivore avoidance of digitalis extracts is not mediated by cardiac glycosides
  582. HIF-1α and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides
  583. High sensitivity of the Na+, K+‐pump of human red blood cells to genins of cardiac glycosides
  584. High-performance liquid chromatographic determination of secondary cardiac glycosides in Digitalis purpurea leaves
  585. High-performance liquid chromatography of cardiac glycosides
  586. High-performance liquid chromatography–ionspray mass spectrometry for the specific determination of digoxin and some related cardiac glycosides in human plasma
  587. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies
  588. HPLC analysis of cardiac glycosides and related steroids
  589. HPTLC PROFILING ON cardiac glycosides OF THEVETIA PERUVIANA LEAF EXTRACTS OF THREE MORPHOVARIANT PLANTS GROWN IN KERALA …
  590. Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells
  591. Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells
  592. Human cell mutants affected in the interaction of the 12β-OH group of cardiac glycosides with the digitalis receptor
  593. Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene
  594. Human hypertensive placenta contains an increased amount of Na, K‐ATPase with higher affinity for cardiac glycosides
  595. Hypotensive effects of cardiac glycosides in spontaneously hypertensive rats.
  596. Hypothesis for the mechanism of stimulation of the Na/K pump by cardiac glycosides—role of endogenous digitalis-like factor
  597. I. Rules of Macrocycle Topology: a [13]-Macrodilactone Case Study II. A cardiac glycoside Activities Link the Ion-transport Function of Na+/K+ ATPase to Breast …
  598. I. SITE-SPECIFIC LABELING OF THE cardiac glycoside RECEPTOR SODIUM AND POTASSIUM ION-ACTIVATED ATPASE; SYNTHESIS OF A C-17 SIDE …
  599. Identification and analysis of cardiac glycosides in Loranthaceae parasites Taxillus chinensis (DC.) Danser and Scurrula parasitica Linn. and their host Nerium …
  600. Identification and characterization of cardiac glycosides as senolytic compounds
  601. Identification and quantification of cardiac glycosides in blood and urine samples by HPLC/MS/MS
  602. Identification and screening of cardiac glycosides in Streptocaulon griffithii using an integrated data mining strategy based on high resolution mass spectrometry
  603. Identification of a Model cardiac glycoside Receptor: Comparisons with Na+,K+-ATPase
  604. Identification of an amino acid substitution in human alpha 1 Na, K-ATPase which confers differentially reduced affinity for two related cardiac glycosides.
  605. Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation
  606. Identification of cardiac glycosides and aglycones in Strophanthus seeds by paper chromatography
  607. Identification of cardiac glycosides as Agonists of RXFP1 via Ultra High Throughput Screening
  608. IDENTIFICATION OF cardiac glycosides FROM THE SEEDS OF DESCURAINIA SOPHIA L. WEBB
  609. Identification of cardiac glycosides in fractions from Periploca forrestii by high-performance liquid chromatography/diode-array detection/electrospray ionization multi …
  610. Identification of cardiac glycosides of Iranian Digitalis species by HPLC
  611. Identification of Na+/K+-ATPase inhibition-independent proarrhythmic ionic mechanisms of cardiac glycosides
  612. Identification of two cardiac glycosides as Na (+)-pump inhibitors in rat urine and diet.
  613. II. The mode of action of cardiac glycosides
  614. Immunochemical comparison of cardiac glycoside-sensitive (lamb) and-insensitive (rat) kidney (Na++ K+)-ATPase
  615. Immunohistochemical identification of endogenous sources of cardiac glycoside biosynthesis
  616. Immunological detection of cardiac glycosides in plants
  617. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice‐based stroke models
  618. In vitro propagation and cardiac glycoside production in endemic Digitalis L. species de Anatolia
  619. In vitro propagation and cardiac glycosides content of Digitalis lanata
  620. In vivo and in vitro studies on Thevetia species growing in Egypt II. Establishment of in vitro tissue culture system and production of cardiac glycosides.
  621. Increase of the extracellular magnesium concentration reduces cardiac glycoside toxicity in the human myocardium.
  622. Increased Ca2+ entry during the plateau of the action potential: a possible mechanism of cardiac glycoside action
  623. Increased dissolution rates of water-insoluble cardiac glycosides and steroids via solid dispersions in polyethylene glycol 6000
  624. Indications and contraindications for therapy with cardiac glycosides
  625. Indications for and use of the cardiac glycosides
  626. Indications, contra-indications and dosage of cardiac glycosides controlled by plasma levels in the aged
  627. Induction of p16INK4a transcription and of cellular senescence by aclacinomycin-derivatives and cardiac glycosides
  628. Inflammasome inhibition blocks cardiac glycoside cell toxicity
  629. Influence of 16β formylation on Na, K-ATPase inhibition by cardiac glycosides
  630. Influence of calcium concentration on the rate of onset of cardiac glycoside and aglycone inotropism.
  631. Influence of canrenoate-K and cardiac glycosides on their tissue distribution and elimination.
  632. Influence of cardiac glycosides on calcium binding in muscle subcellular components
  633. Influence of cardiac glycosides on cell membrane
  634. Influence of cardiac glycosides on electrolyte exchange and content in cardiac muscle cells
  635. Influence of cardiac glycosides on electrophysiologic processes
  636. Influence of cardiac glycosides on myocardial energy metabolism
  637. Influence of cardiac glycosides on pro-and antioxidant systems in normal and hyperbaric oxygenation conditions in acute heart failure
  638. Influence of cardiac glycosides on their receptor
  639. Influence of cardiac glycosides on tissue distribution and elimination of canrenoate
  640. Influence of certain ligands on the dissociation rate constants of cardiac glycoside complexes with sodium-and potassium-dependent adenosine triphosphatase
  641. Influence of derivation on the lipophilicity and inhibitory actions of cardiac glycosides on myocardial Na+‐K+‐ATPase
  642. Influence of Endogenous cardiac glycosides, Digoxin, and Marinobufagenin in the Physiology of Epithelial Cells
  643. Influence of extracellular K+ concentration on the time-course of Na+/K+-ATPase inhibition by cardiac glycosides with fast and low binding kinetics
  644. Influence of high intravenous doses of D-penicillamine on toxic actions of cardiac glycosides in the guinea pig. Short communication (author’s transl)
  645. Influence of Monovalent Cations on the Ca2+-ATPase of Cardiac Sarcoplasmic Reticulum and its Significans of the Positive Inotrop Effect of cardiac glycosides
  646. Influence of the cardiac glycoside digoxin on cardiac troponin I, acid–base and electrolyte balance, and haematobiochemical profiles in healthy donkeys …
  647. INFLUENCE OF THREE cardiac glycosides ON HEMODYNAMIC EFFECTS IN GUINEA PIGS
  648. Influence of thyroid function on the pharmacokinetics of cardiac glycosides
  649. Inhibiting C-Reactive Protein Synthesis by cardiac glycosides in Humans
  650. Inhibition of adrenergic cardiac acceleration by cardiac glycosides
  651. Inhibition of epidermal growth factor signaling by the cardiac glycoside ouabain in medulloblastoma
  652. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin
  653. Inhibition of peripheral blood mononuclear cell proliferation by cardiac glycosides
  654. Inhibition of the sodium pump in squid axons by cardiac glycosides: dependence on extracellular ions and metabolism
  655. INHIBITION OF TNF/NFκB SIGNALING PATHWAY BY DIGITOXIN AND RELATED cardiac glycosides
  656. Inhibitory effects of 6 cardiac glycosides on sodium pump in sheep Purkinje fibers
  657. Inhibitory effects of cardiac glycosides and adrenal steroids on amino acid transport
  658. Inotropic and toxic effects of a polar cardiac glycoside derivative in the dog.
  659. Inotropic Drugs: cardiac glycosides
  660. Insensitivity of lepidopteran tissues to ouabain: physiological mechanisms for protection from cardiac glycosides
  661. Inter-species variations in myocardial responsiveness to cardiac glycosides: possible relations to the thyroid status
  662. Interaction of cardiac glycosides and Na, K-ATPase is regulated by effector-controlled equilibrium between two limit enzyme conformers
  663. Interaction of cardiac glycosides with Na/K-ATPase in intact myocardium
  664. Interaction of DPI 201-106 with cardiac glycosides.
  665. Interaction of palytoxin and cardiac glycosides on erythrocyte membrane and (Na++ K+) ATPase
  666. Interactions between cardiac glycosides and other substances in the body
  667. Interactions between cardiac glycosides and sodium/potassium-ATPase: three-dimensional structure− activity relationship models for ligand binding to the E2-Pi form …
  668. Interactions of cardiac glycosides with cardiac cells. III. Alterations in the sensitivity of (Na++ K+)-ATPase to inhibition by ouabain in rat hearts
  669. Interactions of cardiac glycosides with cells and membranes Properties and structural aspects of two receptor sites for ouabain in erythrocytes
  670. Interactions of cardiac glycosides with cells and membranes. IV. Effects of ouabain and bumetanide on 86Rb+ influx in cultured cardiac myocytes from neonatal rats
  671. Interactions of cardiac glycosides with cultured cardiac cells: II. Biochemical and electron microscopic studies on the effects of ouabain on muscle and non-muscle …
  672. Interactions of cationic drugs and cardiac glycosides at the hepatic uptake level: studies in the ratin vivo, isolated perfused rat liver, isolated rat hepatocytes and …
  673. Interactions of diphenylhydantoin and cardiac glycosides on atrial potassium
  674. Interactions of H ions, Ca-antagonistic drugs and cardiac glycosides with excitation-contraction coupling of vascular smooth muscle
  675. Internalization of ouabain and replacement of sodium pumps in the plasma membranes of HeLa cells following block with cardiac glycosides
  676. Interpretation of post mortem serum levels of cardiac glycosides after suspected overdosage
  677. Intracellular distribution of cardiac glycosides in leaves of Convallaria majalis
  678. Intracellular sodium and the positive inotropic effect of veratridine and cardiac glycoside in sheep Purkinje fibers.
  679. Intracellular taurine and the increased resistance of cardiac myocytes to the calcium paradox, toxic doses of cardiac glycosides and simulated ischemia
  680. Introduction and remarks on the history of cardiac glycosides
  681. Introduction of Adonis aestivalis as a new source of effective cytotoxic cardiac glycoside
  682. Introduction to Symposium on cardiac glycosides
  683. Investigating the anti-cancer properties of cardiac glycosides
  684. Investigation of cardiac glycoside levels in human post mortem blood and tissues determined by a special radioimmunoassay procedure
  685. Investigation of electrophysiologic mechanisms for the antiarrhythmic actions of R 56865 in cardiac glycoside toxicity.
  686. Investigations on cardiac glycosides and interactions with Na⁺, K⁺-ATPase
  687. Involvement of a peripheral mechanism in the emesis induced by cardiac glycosides in Suncus murinus
  688. Involvement of the sugar moiety in the inhibitory action of the cardiac glycosides on the palytoxin-induced responses in vascular smooth muscles.
  689. Ion distribution and myocardial metabolism as affected by cardiac glycosides
  690. Is the Cysteine104 Part of the Sugar Binding Subsite of the cardiac glycoside Receptor of Na+/K+-ATPase?
  691. Is there a need for new cardiac glycosides? For more blood level determinations?
  692. Ischemia-induced alterations in myocardial (Na++ K+)-ATPase and cardiac glycoside binding.
  693. Ischemic striated muscle as an indicator of the activity of a cardiac glycoside
  694. Isoform specificity of cardiac glycosides binding to human Na+, K+-ATPase α1β1, α2β1 and α3β1
  695. Isoform-specific stimulation of cardiac Na/K pumps by nanomolar concentrations of glycosides
  696. Isolation and Identification of Bacterial Diversity from cardiac glycosides Rich Intestine of the Poekilocerus pictus (Fabricius, 1775)
  697. Isolation and quantification of six cardiac glycosides from the seeds of Thevetia peruviana provide a basis for toxological survey
  698. Isolation and structure of two cardiac glycosides from the leaves of Nerium oleander
  699. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain
  700. Kinetic analysis of ouabain binding to native and mutated forms of Na, K-ATPase and identification of a new region involved in cardiac glycoside interactions.
  701. Kinetic and spectroscopic characterisation of the cardiac glycoside binding site of Na+/K+-ATPase employing a dansylated ouabain derivative
  702. Kinetic events determining the effects of cardiac glycosides
  703. Kinetics of active sodium transport in rat proximal tubules and its variation by cardiac glycosides at zero net volume and ion fluxes. Evidence for a multisite sodium …
  704. Kinetics of cardiac glycoside binding to sodium, potassium adenosine triphosphatase studied with a fluorescent derivative of ouabain
  705. kinetics of cardiac glycosides‘
  706. Kinetics of Changes in K+-, Na+- and Ca2+-Content in Heart Tissue in the Presence of cardiac glycosides
  707. Krimpsiekte and acute cardiac glycoside poisoning in sheep caused by bufadienolides from the plant Kalanchoe lanceolata Forsk
  708. Krimpsiekte, associated with thalamic lesions, induced by the neurotoxic cardiac glycoside, cotyledoside, isolated from Tylecodon wallichii (Harv.) Toelken subsp …
  709. L30A mutation of phospholemman mimics effects of cardiac glycosides in isolated cardiomyocytes
  710. Lanatoside C, a cardiac glycoside, acts through protein kinase Cδ to cause apoptosis of human hepatocellular carcinoma cells
  711. Late sodium current inhibition alone with ranolazine is sufficient to reduce ischemia-and cardiac glycoside-induced calcium overload and contractile dysfunction …
  712. LC‐NMR applied to the characterisation of cardiac glycosides from three micropropagated Isoplexis species
  713. Letter in response to “fatal cardiac glycoside poisoning due to mistaking foxglove for comfrey”
  714. Lipophilic character of cardiac glycosides: correlation between RM values and acute toxicity data in different animal species
  715. Lipophilic character of cardiac glycosides: RM values as lipophilicity parameters
  716. Lipophilicity and pharmacodynamics of cardiac glycosides
  717. Liquid chromatographic detection of cardiac glycosides and saccharides based on the photoreduction of anthraquinone-2, 6-disulfonate
  718. Liquid chromatographic detection of cardiac glycosides, saccharides and hydrocortisone based on the photoreduction of 2-tert-butylanthraquinone
  719. Liquid chromatography of cardiac glycosides
  720. Liver cell potentials: In vitro effects of metabolic inhibitors, cardiac glycosides, and hormones
  721. Locus of the central emetic action of cardiac glycosides.
  722. Magnesium lithospermate B extracted from Salvia miltiorrhiza, a potential substitute for cardiac glycosides
  723. Management of plant cardiac glycoside poisoning
  724. Maquiroside A, a new cytotoxic cardiac glycoside from Maquira calophylla
  725. Mass spectrometric analysis of cardiac glycosides by the desorption/ionization technique potassium ion ionization of desorbed species
  726. Measurement of cardiac glycoside concentrations in serum or plasma: Technical problems and clinical implications
  727. Measurement of Serum cardiac glycoside Levels: Using Pharmacologic Principles to Solve Crossreactivity Problems
  728. Mechanism of antilipolytic effects of cardiac glycosides
  729. Mechanism of cardiac glycoside inhibition of the (Na+-K+)-dependent ATPase from cardiac tissue
  730. Mechanism of cardiac glycoside-induced toxicity: physiology, biochemistry, and electron microscopy.
  731. Mechanism of inhibition by SUN 1165, a new Na channel blocking antiarrhythmic agent, of cardiac glycoside-induced triggered activity
  732. Mechanism of the inhibitory effects of cardiac glycosides on lipolysis
  733. Mechanisms for cardiac glycoside-induced Wenckebach periods in canine Purkinje strands
  734. Mediation of cardiac glycoside insensitivity in the monarch butterfly (Danaus plexippus): Role of an amino acid substitution in the ouabain binding site of Na+,K+ …
  735. Medicinal plants, containing cardiac glycosides and their distribution
  736. Membrane currents and tension in cat ventricular muscle treated with cardiac glycosides.
  737. Membrane receptor calorimetry: cardiac glycoside interaction with Na, K-ATPase
  738. Membrane-bound Na+,K+-ATPase as the cardiac glycoside receptor: A thermochemical characterization
  739. Meproscillarin, a new semisynthetic cardiac glycoside/chemistry and physical properties (author’s transl)
  740. Metabolic action of the cardiac glycosides III. Influence of ouabain on the utilization of C14-labeled glucose, lactate, and pyruvate by dog heart slices
  741. Metabolic action of the cardiac glycosides: I. Influence on respiration of heart muscle and brain cortex
  742. Metabolic action of the cardiac glycosides. II. Effect of ouabain and digoxin on the energy-rich phosphate content of the heart
  743. Metabolic fate of cardiac glycosides and flavonoids upon fermentation of aqueous sea squill (Drimia maritima L.) extracts
  744. Metabolic turnover and effect of cardiac glycosides. I. Determination of blood levels and of the ventricular ejection index and of RI time derivated from apex cardiogram …
  745. Metabolism of cardiac glycosides studied in the isolated perfused guinea‐pig liver
  746. Metabolism of cardiac glycosides—II: Cardiotoxicity of metabolites of digitoxin-7αT
  747. Metabolism of cardiac glycosides. A review of the absorption, metabolism and excretion of clinically important cardiac glycosides: By SC Wright. Charles C Thomas …
  748. Method validation of a survey of thevetia cardiac glycosides in serum samples
  749. Methods for the determination of cardiac glycosides
  750. Micro high-performance liquid chromatographic determination of cardiac glycosides in β-methyldigoxin and digoxin tablets
  751. Micro HPLC separation of 3, 5-dinitrobenzoyl derivatives of cardiac glycosides and their metabolites
  752. Micro-determination of cardiac glycosides by Mean of the Embryonic Heart of Japanese Killifish, Oryzias Latipes (I): ACTION OF HYALURONIDASE
  753. Micro-determination of cardiac glycosides by Means of the Embryonic Heart of Japanese Killifish Oryzias Latipes (III): ACTION OF cardiac glycosideRS UNDER …
  754. Micro-determination of cardiac glycosides by Means of the Embryonic Heart of Japanese Killifish, Oryzias Latipes (II): ACTION OF cardiac glycosides ON THE …
  755. Microbiological exploitation of cardiac glycosides and alkaloids from Garcinia kola, Borreria ocymoides, Kola nitida and Citrus aurantifolia
  756. Microscopic study of plants containing cardiac glycoside in Apocynaceae
  757. Microwave Extraction of cardiac glycosides from Milkweed Leaves
  758. Modification of atrioventricular conduction under the combined influence of a cardiac glycoside and a calcium antagonist in the dog.
  759. Modification of the positive inotropic effects of catecholamines, cardiac glycosides and Ca2+ by the orally active male contraceptive, gossypol, in isolated guinea-pig …
  760. Modulation of cardiac glycoside inhibition of (Na++ K+)-ATPase by membrane lipids. Difference between species
  761. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain
  762. Modulation of Glycoside Sensitivity of the Cardiac Sodium Pump
  763. Molecular basis for the insensitivity of the Monarch (Danaus plexippus) to cardiac glycosides
  764. Molecular modeling of cardiac glycoside binding by the human sequence monoclonal antibody 1B3
  765. Molecular pharmacology of cell receptors for cardiac glycosides, opiates, ACTH and ion channel modulators
  766. Molluscicidal activity of cardiac glycosides from Nerium indicum against Pomacea canaliculata and its implications for the mechanisms of toxicity
  767. Molluscicidal activity of cardiac glycosides isolated from Adenium
  768. Molluscicidal activity of cardiac glycosides isolated from Adenium obesum
  769. Morphological basis of cardiac glycoside sequestration by Oncopeltus fasciatus (Dallas) (Hemiptera: Lygaeidae)
  770. Morphological examination of cardiac glycoside in myocardial cells.
  771. Multiple forms of the cardiac glycoside receptor with different affinities for cardiac glycosides
  772. Multiplicity of cardiac glycoside receptors in the heart
  773. Mutants of HeLa cells resistant to ouabain and cassaine: Genetic evidence for the common site of action of cardiac glycosides and erythrophleum alkaloids
  774. Myocardial contraction frequency and onset of cardiac glycoside action
  775. Na (+)-channel activators increase cardiac glycoside sensitivity in failing human myocardium.
  776. Na K ATPase sensitivity to cardiac glycosides in hypertrophied guinea pig left ventricles
  777. Na, K-ATPase and cardiac glycosides: new functions of the known protein
  778. Na, K-ATPase from placenta of women with pregnancy-induced hypertension exhibits an increased affinity for cardiac glycosides
  779. Na, K-ATPase: cardiac glycoside Binding and Functional Importance of Negatively Charged Amino Acids of Transmembrane Regions
  780. Na+, K+-ATPase inhibiting activity of cardiac glycosides from Erysimum cheiranthoides
  781. Nadph Oxidase-Stimulated Mitochondrial Radical Release Contributes to Arrhythmic Toxicity of cardiac glycosides by Redox Modification of Ryanodine …
  782. Naturally occurring cardiac glycosides
  783. Nature of the Schwann Cell Electrical Potential: Effects of the external ionic concentrations and a cardiac glycoside
  784. Nature of the transport adenosine triphosphatase-digitalis complex: XIV. Inotropy and cardiac glycoside interaction with Na+, K+-ATPase of isolated cat papillary …
  785. Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity
  786. Neurally mediated augmentation of arrhythmogenic properties of highly polar cardiac glycosides
  787. Neuroprotective and tumoricidal activities of cardiac glycosides. Could oleandrin be a new weapon against stroke and glioblastoma?
  788. New aspects on the mode of action of cardiac glycosides
  789. New cardiac glycosides containing 2-deoxyhexoses from the defensive secretion of adult Chrysolina banksi (Coleoptera: Chrysomelidae)
  790. New cardiac glycosides from Digitalis lanata.
  791. New Cleavage Methods for cardiac glycosides having a Doubly Linked Sugar1
  792. New developments in cardiac glycoside structure-activity relationships
  793. New knowledge about old drugs: the anti-inflammatory properties of cardiac glycosides
  794. New semisynthetic cardiac glycosides and their biological activity
  795. New steroid hormone family: endogenous cardiac glycosides and their role in physiologic and pathologic conditions
  796. New targets for old drugs: cardiac glycosides inhibit atrial-specific K2P3. 1 (TASK-1) channels
  797. New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin
  798. New therapeutic effects of cardiac glycoside: anti-cancer and anti-aging
  799. Newer cardiac glycosides and aglycones
  800. Newman RA, Yang P, Pawlus AD, Block KI.. cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8: 36-49
  801. Nigericin decreases the viability of multidrug-resistant cancer cells and lung tumorspheres and potentiates the effects of cardiac glycosides
  802. Non-specificity of the effect of cardiac glycosides on the polymerization of actin
  803. Nontargeted Profiling of Specialized Metabolites of Digitalis purpurea with a Focus on cardiac glycosides
  804. Not all cardiac glycosides are equal: Could ouabain prove to be better than digoxin for heart failure?
  805. Novel therapeutic applications of cardiac glycosides
  806. Oleandrin and its derivative odoroside a, both cardiac glycosides, exhibit anticancer effects by inhibiting invasion via suppressing the stat-3 signaling pathway
  807. Oleandrin: A cardiac glycosides with potent cytotoxicity
  808. On the connection between cardiac glycosides
  809. On the connection between cardiac glycosides and calcium action
  810. On the lack of inotropy of cardiac glycosides on skeletal muscle: a comparison of Na+, K+-ATPases from skeletal and cardiac muscle
  811. On the Mechanism of cardiac glycoside Action: Stimulation of Myosin B Superprecipitation by Ouabain and Digoxin
  812. On the ocular distribution of cardiac glycosides in guinea pigs following acute administration
  813. On the rational choice of cardiac glycoside
  814. On the sarcolemmal site of action of cardiac glycosides.
  815. On the therapeutic mechanism of Mg2+ in digitoxic arrhythmias and the role of cardiac glycosides in Mg depletion.
  816. Optimization and validation of a high-performance liquid chromatography method for the analysis of cardiac glycosides in Digitalis lanata
  817. Optimization of therapy using cardiac glycosides
  818. Organic anion transporting polypeptide 1a4 is responsible for the hepatic uptake of cardiac glycosides in mice
  819. Origin of differences of inhibitory potency of cardiac glycosides in Na+/K+-transporting ATPase from human cardiac muscle, human brain cortex and guinea-pig …
  820. Ouabain and Endogenous Ouabain-Dr. Jekyll and Mr. Hyde of cardiac glycosides?
  821. Ouabain, a cardiac glycoside, inhibits the Fanconi Anemia-BRCA pathway activated by DNA crosslinking agents.
  822. Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents
  823. Palytoxin induces a relatively non-selective cation permeability in frog sciatic nerve which can be inhibited by cardiac glycosides
  824. Paper Chromatography of cardiac glycosides and Aglyeones from Digitalis Purpurea
  825. Participation of trigger membrane mechanisms in the effect of cardiac glycosides on the heart
  826. Penta-acetyl-gitoxin: the prototype of a prodrug in the cardiac glycoside series.
  827. Perfectly regioselective acylation of a cardiac glycoside, digitoxin, via catalytic amplification of the intrinsic reactivity
  828. Peruvoside, a cardiac glycoside, induces primitive myeloid leukemia cell death
  829. Pharmaceutical Quality Control Standards for cardiac glycosides
  830. Pharmacokinetics of cardiac glycosides and clinical consequences
  831. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides
  832. Pharmacological effects of cardiac glycosides on cell death and autophagy: Impact on the mitochondrial network structure and function
  833. Pharmacological studies of a new 4-aminosugar cardiac glycoside (ASI-222).
  834. Pharmacological Therapy of Cardiac Arrhythmias: Antiarrhythmic Agents, Beta Adrenoceptor Blocking Agents, and Digitalis Glycosides
  835. Pharmacological treatment of cardiac glycoside poisoning
  836. Pharmacology of cardiac glycosides
  837. Pharmacology of cardiac glycosides
  838. Pharmacology of sixty-four cardiac glycosides and aglycones
  839. Photoaffinity labeling of the sodium-and potassium-activated adenosinetriphosphatase with a cardiac glycoside containing the photoactive group on the C-17 side …
  840. Physico-chemical applications of liquid chromatography I. Investigation of the adsorption of cardiac glycosides from water-ethanol solutions on silanized silica
  841. Physiological role of the α1- and α2-isoforms of the Na+-K+-ATPase and biological significance of their cardiac glycoside binding site
  842. Plant anticancer agents, XLI. cardiac glycosides from Streblus asper
  843. Plant cardiac glycosides and digoxin Fab antibody
  844. Plant poisonings: common plants that contain cardiac glycosides
  845. Plant-derived cardiac glycosides: Role in heart ailments and cancer management
  846. Plants and cardiac glycosides.
  847. Plants containing cardiac glycosides showing antiphytoviral activity against Potato virus Y (PVYNTN) on tobacco plants
  848. Plasma concentration and elimination behavior of the cardiac glycoside meproscillarin in patients with liver cirrhosis
  849. Plasma concentration, uptake by liver, and biliary excretion of tritiated cardiac glycosides in the isolated perfused guinea‐pig liver
  850. Plasma concentrations of cardiac glycosides in digitalis intoxication
  851. Plasma protein binding of cardiac glycosides
  852. Plasma-tissue distribution of different cardiac glycosides
  853. Pluripotent Stem Cell-Based Drug Screening Reveals cardiac glycosides as Modulators of Myotonic Dystrophy Type 1
  854. Possible involvement of cardiac Na+, K+-adenosine triphosphatase in the mechanism of action of cardiac glycosides
  855. Possible usefulness of cardiac glycosides in treatment of glaucoma
  856. Potassium changes the relationship between receptor occupancy and the inotropic effect of cardiac glycosides in guinea‐pig myocardium
  857. Potassium ions and the binding of cardiac glycosides to mammalian cells
  858. Potential anticancer agents. V. cardiac glycosides of Asclepias albicans (Asclepiadaceae)
  859. Potential drug interactions in heart failure patients involving cardiac glycosides
  860. Potentiation of adrenergic venomotor responses in dogs by cardiac glycosides
  861. Pre-and Post-conditioning by cardiac glycosides in the Mouse Heart.
  862. Preconditioning and postconditioning by cardiac glycosides in the mouse heart
  863. Preferential sensitivity of the left canine purkinje system to cardiac glycosides.
  864. Preparation and evaluation of technetium-99m labeled cardiac glycoside derivatives as potential myocardial imaging agent
  865. Preparation of an analogue of orbicuside A, an unusual cardiac glycoside
  866. Pressor and vascular effects of cardiac glycosides
  867. Pressure-induced cardiac hypertrophy: changes in Na+, K+-ATPase and glycoside actions in cats
  868. Problems in the use of cardiac glycosides in ischemic heart disease
  869. Problems of combined therapy with cardiac glycosides and anti-anginal drugs (author’s transl)
  870. Proceraside A, a new cardiac glycoside from the root barks of Calotropis procera with in vitro anticancer effects
  871. Production of cardiac glycosides by chrysomelid beetles and larvae
  872. Production of cardiac glycosides by plant tissue cultures I: Nutritional requirements in tissue cultures of Digitalis lanata and Digitalis purpurea
  873. Production of cardiac glycosides by plant tissue cultures iv biotransformation of digitoxigenin and related substances
  874. Prognosis of the effect of cardiac glycosides on the extrasystole in ischemic heart disease
  875. Proscillaradin A: From cardiac glycosides to Cancer Therapeutics
  876. Prospecting endophytic fungal assemblage of Digitalis lanata Ehrh. (foxglove) as a novel source of digoxin: a cardiac glycoside
  877. Protection of cardiac glycosides from Action of Light by Actinic Desensitizer (Red Dye)
  878. Protective action of cardiac glycosides and adrenal cortical hormone against thyroxin
  879. Protein binding of cardiac glycosides in disease states
  880. Proximate and cardiac glycoside Composition of Thevetia (Thevetia neriifolia. JUSS) Seed as Affected by Soaking in Water, Brine and Ethanol
  881. PST 2238 as an antihypertensive compound that antagonizes the effect of endogenous cardiac glycosides
  882. Qualitative and quantitative HPLC-analysis of cardiac glycosides
  883. Quantitative Analysis of cardiac glycosides in Digitalis purpurea and Digitalis lanata with HPLC
  884. Quantitative aspects of specific binding of cardiac glycosides to membrane receptors
  885. Quantitative correlation of cardiac glycoside binding to its receptor and inhibition of the sodium pump in chicken heart cells in culture
  886. Quantitative determination of cardiac glycosides in Digitalis lanata leaves by reversed-phase thin-layer chromatography
  887. Quantitative fluorimetric determination of the main cardiac glycosides in Digitalis purpurea leaves
  888. Quantitative HPLC analysis of cardiac glycosides in Digitalis purpurea leaves
  889. Quantitative variations in the cardiac glycosides of oleander
  890. Radioimmunoassay of cardiac glycosides in haemolysed blood: derivation of serum levels
  891. Radioimmunological estimation of cardiac glycoside concentration in the plasma
  892. Rapid detection of the active cardiac glycoside convallatoxin of lily of the valley using LOCI digoxin assay
  893. Reactions of various predators to insects storing heart poisons (cardiac glycosides) in their tissues
  894. Reappraisal of digitalis. Part II. Hemodynamic effects of the cardiac glycosides
  895. Recent advances in cardiac glycoside-Na+, K+-ATPase interaction.
  896. Recent progress in the biochemistry of plant steroids other than sterols (saponins, glycoalkaloids, pregnane derivatives, cardiac glycosides, and sex hormones)
  897. Recent progress on anti-cancer effect of cardiac glycosides [J]
  898. Receptor for cardiac glycosides
  899. Receptor kinetics and concentration-effect relation of cardiac glycosides.
  900. Red cell Na+, K+-ATPase: a method for estimating the extent of inhibition of an enzyme sample containing an unknown amount of bound cardiac glycoside
  901. Reduction of the equilibrium binding of cardiac glycosides and related compounds to Na+, K+-ATPase as a possible mechanism for the potassium-induced reversal …
  902. Regioselective diversification of a cardiac glycoside, lanatoside C, by organocatalysis
  903. Regulation of myofibroblast differentiation and pulmonary fibrosis by cardiac glycosides
  904. Regulation of myofibroblast differentiation by cardiac glycosides
  905. Regulation of therapeutic and toxic effects of cardiac glycosides by electromagnetic radiations, alternating magnetic and electric fields
  906. Relation between intracellular sodium and twitch tension in sheep cardiac Purkinje strands exposed to cardiac glycosides.
  907. Relationship between cardiac glycoside contents and color of Corchorus olitorius seeds
  908. Relationship between the chemical structure and pharmacological action of cardiac glycosides of the strophanthidin series
  909. Release of adenine nucleotide metabolites by toxic concentrations of cardiac glycosides
  910. Relevant metabolism of cardiac glycosides
  911. RELIMINARY STUDIES ON EXTRACTION OF TOTAL cardiac glycoside FROM THE CALLOSITY OF DIGITALIS PURPUREA L
  912. Renal tubular transport of a polar cardiac glycoside, ASI-222, in rats; Clearance and micropuncture studies
  913. Repeated unexplained cardiac glycoside poisoning
  914. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation
  915. Research Advances of Anti-tumor Effect of cardiac glycosides [J]
  916. Research Report 2: The role of Pgp in zebrafish cardiac glycosides chronotoxicity
  917. Respiratory actions of the cardiac glycoside, ouabain
  918. Response of large and small coronary arteries to adenosine, nitroglycerin, cardiac glycosides, and calcium antagonists
  919. RETRACTED ARTICLE: cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of …
  920. Reversed-phase high-performance liquid chromatography of the cardiac glycoside LNF-209 with refractive index detection
  921. Reversible inhibition of (Na++ K+)-ATPase with a cardiac glycoside
  922. Reversing life-threatening cardiac glycoside intoxication with digoxin immune Fab
  923. Review on cardiac glycosides in cancer research and cancer therapy
  924. Revisiting the binding kinetics and inhibitory potency of cardiac glycosides on Na+, K+-ATPase (α1β1): Methodological considerations
  925. Rhodexin A and B, New cardiac glycosides of Rhodea japonica, Roth
  926. Rhythm and conduction disorders caused by cardiac glycosides
  927. Robust reference gene design and validation for expression studies in the large milkweed bug, Oncopeltus fasciatus, upon cardiac glycoside stress
  928. Role of cardiac glycosides in regulation of the growth of retinal tissue explants
  929. Role of endogenous cardiac glycosides in the spontaneously hypertensive rat—antagonism by active immunization
  930. Role of homologous ASP334 and GLU319 in human non-gastric H, K-and Na, K-ATPases in cardiac glycoside binding
  931. Role of induction forces interactions in effecting gas chromatographic separation of cardiac glycoside trimethylsilyl ethers
  932. Role of mitochondrial dysfunction in cardiac glycoside toxicity
  933. Role of the Na+ K+-ATPase in the cardiotonic action of cardiac glycosides.
  934. Ryanodine receptor phosphorylation by oxidized CaMKII contributes to the cardiotoxic effects of cardiac glycosides
  935. RyR Phosphorylation by Oxidized CaMKII Contributes to the Cardiotoxic Effects of cardiac glycosides
  936. Screening for cardiac glycosides in Schizobasis intricata
  937. Selection of Monoclonal Anti-Digoxin Antibodies Suitable for Monitoring of cardiac glycosides
  938. Selective anticancer mechanisms of cardiac glycosides and related antitumor drugs: research advances
  939. Selective inhibition of human erythrocyte Na+/K+ ATPase by cardiac glycosides and by a mammalian digitalis like factor
  940. Selective uptake and vacuolar storage of primary cardiac glycosides by suspension-cultured Digitalis lanata cells
  941. Sensitivity of the failing and nonfailing human heart to cardiac glycosides
  942. Separation and determination of cardiac glycosides in Digitalis purpurea leaves by micro high-performance liquid chromatography
  943. SEPARATION AND DETERMINATION OF RELATIVE CONTENT OF cardiac glycosides FROM ADONIS AMURENSIS WITH HIGH-PERFORMANCE LIQUID …
  944. Separation and identifying features of the cardiac aglycones and glycosides of Nerium oleander L. flowers by thin-layer chromatography
  945. Separation of a cardiac glycoside from Penstemon grandiflorus
  946. Separation of cardiac glycosides by micellar electrokinetic capillary electrophoresis.
  947. Separation of cardiac glycosides by micellar electrokinetic chromatography and microemulsion electrokinetic chromatography
  948. Separation of cardiac glycosides by Thin-Layer Chromatography
  949. Separation of insulin effects on K content and O2 consumption of frog muscle with cardiac glycosides
  950. Sequence data of mitochondrial 16S rDNA of Arctiidae and Nymphalidae: evidence for a convergent evolution of pyrrolizidine alkoloid and cardiac glycoside …
  951. Serum cardiac glycoside Assay Based upon Displacement of 3H-Ouabain from Na-K ATPase
  952. Serum concentration monitoring of cardiac glycosides
  953. Side effects and intoxication of cardiac glycosides: manifestations and treatment
  954. Simultaneous analysis of cardiac glycosides in blood and urine by thermoresponsive LC-MS-MS
  955. Simultaneous determination of various cardiac glycosides by liquid chromatography–hybrid mass spectrometry for the purity assessment of the therapeutic monitored …
  956. Singular effects of a new short acting cardiac glycoside in Purkinje cells
  957. Site of cardiac glycoside inhibition of cation transport
  958. Site-specific labeling of the cardiac glycoside receptor Na⁺, K⁺-ATPase: synthesis of a C-17 side group photoaffinity label; Relationship of cardioactive steroid …
  959. Skeletal muscle Na, K-pump concentration in children and its relationship to cardiac glycoside distribution.
  960. Smooth muscle and cardiac glycosides (author’s transl)
  961. Sodium dependence of the positive inotropic effect of cardiac glycosides.
  962. Sodium-dependent cardiac glycoside binding: experimental evidence and hypothesis.
  963. Sodium/potasium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: a new paradigm for development of anti- breast cancer drugs?
  964. Sodium/potasium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: a new paradigm for development of anti-breast cancer drugs?
  965. Some observations on the interaction between cardiac glycosides and reserpine in the heart and central nervous system
  966. Some substances with proposed digitalis-like effects evaluated on platelet functions sensitive for cardiac glycosides
  967. Spatial relationship and conformational changes between the cardiac glycoside site and. beta.-subunit oligosaccharides in sodium plus potassium activated …
  968. Specific binding of cardiac glycoside drugs and endogenous digitalis-like substances to particulate membrane fractions from human placenta.
  969. Specificity of cardiac glycoside binding to membrane filters
  970. Specificity of the effects of cardiac glycosides on the rhythmic contraction of single cultured cardiac muscle cells
  971. Spectrophotometric determination of cardiac glycosides by flow-injection analysis
  972. Spin-labeled ouabain as a probe for cardiac glycoside receptor/Na, K-ATPase
  973. Spiroergometric evaluation of the effectiveness of treatment of cardiac insufficiency with cardiac glycosides
  974. Src mediates extracellular signal‐regulated kinase 1/2 activation and autophagic cell death induced by cardiac glycosides in human non‐small cell lung cancer cell …
  975. Stability of cardiac glycosides in aqueous and fermented aqueous extracts from sea squill (Drimia maritima L. Stearn).
  976. Stereoselective inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes
  977. Steroidal sapogenins XL. Simplified procedure for the qualitative detection of cardiac glycosides
  978. Stimulation and Inhibition of the Na+, K+-Pump by cardiac glycosides
  979. Stimulation of Monovalent Cation Active Transport by Low Concentrations of cardiac glycosides: ROLE OF CATECHOLAMINES
  980. Storage of cardiac glycosides in vacuoles of Digitalis lanata mesophyll cells
  981. Structural analysis of bufadienolide and cardenolide type cardiac glycosides by fast atom bombardment mass spectrometry
  982. Structural analysis of cardiac glycosides to determine the basis for tumoristatic activity
  983. Structural and functional investigation of Na+, K+-ATPase regulators: FXYD proteins and cardiac glycosides
  984. Structural complexes in the squid giant axon membrane sensitive to ionic concentrations and cardiac glycosides
  985. Structural elucidation and evaluation of toxicity and antitumor activity of cardiac glycosides isolated from Leptadenia pyrotechnica
  986. Structural insights into the binding of cardiac glycosides to the digitalis receptor revealed by solid-state NMR
  987. Structural studies on the cardiac glycoside receptor
  988. Structure-activity correlation of the lethality and central effects of selected cardiac glycosides
  989. Structure-activity relationships of an aminosugar cardiac glycoside, ASI-222 HCl, in the heart-lung preparation of the dog.
  990. Structure-activity relationships of synthetic cardiac glycosides
  991. Structure-specificity relationship of cardiac glycosides as a substrate for glucohydrolase II
  992. Structures of elaeodendrosides B, C, F, G, K and L, a series of cardiac glycosides isolated from Elaeodendron glaucum
  993. STUDIES OF THE ANTIMITOTIC EFFECTS OF cardiac glycosides: MOLECULAR FEATURES AND POTENCY
  994. Studies of the clinical pharmacology of cardiac glycosides
  995. Studies of the electrocardiogram and the toxicity of cardiac glycosides in animals exposed to hyperbaric helium
  996. Studies of the inotropic mechanisms of cardiac glycosides
  997. Studies of the inotropic mechanisms of cardiac glycosides in cultured heart cells
  998. Studies on a plasma cardiac glycoside assay based upon displacement of3H-ouabain from Na+−K+-ATPase
  999. Studies on cardioactive steroids. III. Characterization of different cardiac glycosides by their effects on contractility and rhythmicity at different extracellular potassium …
  1000. Studies on Cerbera. I. cardiac glycosides in the seeds, bark, and leaves of Cerbera manghas L.
  1001. Studies on cytotoxic and neutrophil challenging polypeptides and cardiac glycosides of plant origin
  1002. Studies on digitalis: XV. Effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart
  1003. Studies on sodium-potassium-activated adenosinetriphosphatase. IV. Correlation with cation transport sensitive to cardiac glycosides
  1004. Studies on South African cardiac glycosides. I. Isolation of toxic principles of Homeria glauca (W. & E.) NE Br. and observations on their chemical and pharmacological …
  1005. Studies on South African cardiac glycosides. II. Observations on the clinical and haemodynamic effects of cotyledoside
  1006. Studies on the Biosynthes is of cardiac glycosides: Enzymatic Synthesis of [14C-Glucose]-Glucoevatromonoside
  1007. Studies on the Biosynthesis of cardiac glycosides: Fucosyltransferase Activity in Leaves of Digitalis lanata
  1008. STUDIES ON THE cardiac glycosides OF THEVETIA PERUVIANA MERR. SYN. THEVETIA NERIIFOLIA JUSS.——Ⅱ. ISOLATION AND IDENTIFICATION OF …
  1009. Studies on the Constituents of Mallotus japonicus MUELL. ARG. I. cardiac glycosides from the Seeds
  1010. Studies on the localization of the cardiac glycoside receptor
  1011. Studies on the mechanism of cardiac glycoside action
  1012. Studies on the mechanism of cardiotonica with reference to the cardiac glycoside, calcium ion and myocardial catecholamine in the canine heart
  1013. Studies on the mechanism of inhibition of the red cell metabolism by cardiac glycosides.
  1014. Studies on the optimization of parameters of preparative liquid chromatographic columns for production of cardiac glycosides
  1015. Studies on veratrum alkaloids. XVII. The antiveratrinic action of the cardiac glycosides and of bufotoxin
  1016. Studies related to the mechanism of action of cardiac glycosides. On the reactions of thiols with unsaturated lactones and on the structure of the compound previously …
  1017. Studies to determine the adaptability of the staircase phenomenon to the assay of cardiac glycosides
  1018. Study on the production of cardiac glycosides in direct regenerated shoots of Foxglove (Digitalis nervosa).
  1019. Subcellular and molecular mechanisms of the effects of cardiac glycosides and angiotensin-converting enzyme inhibitors on contractile function and energy …
  1020. SUBCELLULAR DISTRIBUTION OF cardiac glycosides IN RABBIT AND RAT MYOMETRIUM AND THEIR BINDING TO ISOLATED PLASMA MEMBRANE
  1021. Subcellular localization of glucosyltransferases involved in cardiac glycoside glucosylation in leaves of Convallaria majalis
  1022. Subcellular Localization of Primary and Second cardiac glycosides, and the Related 16′-O-Glucosyl-Transferase in Cell Suspension Cultures of Digitalis Lanata
  1023. Subchronic treatment with vanadate does not potentiate the toxicity of cardiac glycosides
  1024. Subclassification of cardiac glycoside receptors
  1025. Submolecular mechanisms underlying in vitro and in vivo effect of cardiac glycosides on contractile activity of myocardial myofibrils during heart failure
  1026. Substances possessing inotropic properties similar to cardiac glycosides
  1027. Successful treatment of oleander intoxication (cardiac glycosides) with digoxin-specific Fab antibody fragments in a 7-year-old child
  1028. Sugar moiety of cardiac glycosides is essential for the inhibitory action on the palytoxin‐induced K+ release from red blood cells
  1029. Suppression of mouse lymphocytic mouse leukemia L1210 cells growth by cardiac glycosides
  1030. Suppression of positive inotropic and toxic effects of cardiac glycosides by amiloride
  1031. Survival of first instar larvae ofDanaus plexippus (Lepidoptera: Danainae) in relation to cardiac glycoside and latex content ofAsclepias humistrata (Asclepiadaceae)
  1032. Suspected cardiac glycoside intoxication in sheep and goats in Namibia due to Ornithogalum nanodes (Leighton)
  1033. Synergism in the action of gamma radiation and cardiac glycosides
  1034. Synergitic Effect the cardiac glycosides on Antitumor Activity of vincristin in vitro and in vivo
  1035. Synthesis and evaluation of cardiac glycoside mimics as potential anticancer drugs
  1036. Synthesis and structure-activity relationships of 14β-hydroxy-5α-pregnanes: pregnanes that bind to the cardiac glycoside receptor
  1037. Synthesis of BCD tricyclic analogues of the novel cardiac glycoside rhodexin A
  1038. Synthesis of cardiac glycoside analogs by catalyst-controlled, regioselective glycosylation of digitoxin
  1039. SYNTHESIS OF MONO AND DI DIGOXIGENIN AND STROPHANTHIDIN cardiac glycosides.
  1040. Synthetic approach to the core structure of Oleandrin and related cardiac glycosides with highly functionalized ring D
  1041. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy
  1042. Tannin, oxalate, saponin, cyanogenic and cardiac glycosides contents of cola ntida and cola acuminata
  1043. Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma
  1044. Targeting MYC overexpressing leukemia with cardiac glycoside proscillaridin through downregulation of histone acetyltransferases
  1045. Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients’ own erythrocytes during glycoside therapy
  1046. Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients’ own tissues during glycoside therapy
  1047. Tensammetric Detection in High Performance Liquid Chromatography. Application to Lynestrenol and Some cardiac glycosides
  1048. The “endogenous cardiac glycoside”
  1049. The action of a number of cardiac glycosides on an isolated system of myocardial contractile proteins in heart failure due to toxic-allergic myocarditis. The molecular …
  1050. The Action of cardiac glycosides in Cardiac Insufficiency
  1051. The action of cardiac glycosides on autonomic ganglia
  1052. The action of cardiac glycosides on experimental auricular flutter
  1053. The action of cardiac glycosides on sodium and potassium movements in human red cells
  1054. The action of cardiac glycosides on the excitability and conduction velocity of the mammalian atrium
  1055. The action of cardiac glycosides on the refractory period of heart tissues
  1056. The action of salicylate, dinitrophenol and cardiac glycosides on the isolated toad heart.
  1057. The action of several cardiac glycosides on conduction velocity and ventricular excitability in the dog heart
  1058. The actions of cardiac glycosides on heart muscle cells
  1059. The actions of digitalis leaf preparations and of cardiac glycosides on the isolated right ventricle of the guinea pig
  1060. The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early …
  1061. The alpha-synuclein 5′ untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen
  1062. The antitoxic action of triamterene in cardiac glycoside poisoning
  1063. The binding of cardiac glycosides to bull spermatozoa
  1064. The bioavailability of methylepoxyproscillaridin (P35): a new semisynthetic cardiac glycoside.
  1065. The carbohydrate components of the cardiac glycosides
  1066. The carbohydrate moieties of the beta-subunit of Na+, K (+)-ATPase: their lateral motions and proximity to the cardiac glycoside site
  1067. The cardiac glycoside binding site on the Na, K-ATPase α2 isoform plays a role in the dynamic regulation of active transport in skeletal muscle
  1068. The cardiac glycoside convallatoxin inhibits the growth of colorectal cancer cells in a p53-independent manner
  1069. The cardiac glycoside digoxin does not alter the activity of human polymorphonuclear leukocytes in vitro
  1070. The cardiac glycoside from Urginea rubella Baker. Part II. Hydrolysis of rubellin and pro-rubellidin
  1071. The cardiac glycoside from Urginea rubella Baker. Part. I. Isolation and properties of rubellin
  1072. The cardiac glycoside oleandrin induces apoptosis in human colon cancer cells via the mitochondrial pathway
  1073. The cardiac glycoside ouabain activates NLRP3 inflammasomes and promotes cardiac inflammation and dysfunction
  1074. The cardiac glycoside ouabain potentiates excitotoxic injury of adult neurons in rat hippocampus
  1075. The cardiac glycoside receptor: its properties and its correlation to nucleotide binding sites, phosphointermediate, and (Na++ K+)-ATPase activity.
  1076. The cardiac glycoside sensitive step in the hepatic transport of the bisquaternary ammonium compound, hexafluorenium
  1077. The cardiac glycoside-receptor system in the human heart
  1078. The cardiac glycosides
  1079. The cardiac glycosides
  1080. The cardiac glycosides digitoxin, digoxin and ouabain induce a potent inhibition of glycolysis in lung cancer cells
  1081. The cardiac glycosides Digitoxin, Digoxin and Ouabain Induce a Potent Inhibition of Glycolysis in Lung Cancer Cells
  1082. The cardiac glycosides in medical practice
  1083. The cardiac glycosides of Cerbera species. I. The isolation of cerbertin and cerbertatin
  1084. The cardiac glycosides of Gomphocarpus fruticosus R. Br. II. Gomphoside
  1085. The cardiac glycosides of Gomphocarpus fruticosus R. Br. III. Gomphoside
  1086. The cardiac glycosides of Gomphocarpusf ruticosus R. Br. I. Afroside
  1087. The cardiac glycosides present in mistletoes growing on Nerium oleander
  1088. The chemistry of cardiac glycosides in the Soviet Union
  1089. The Chemistry of the cardiac glycosides.
  1090. The comparative acute toxicity of two cardiac glycosides in adult and newborn rats
  1091. The comparative efficacy and differences in the molecular mechanism of the inotropic action of cardiac glycosides and nonglycoside cardiotropic agents on the …
  1092. The confromational behaviour of the cardiac glycoside digoxin as indicated by NMR spectroscopy and molecular dynamics calculations
  1093. The connection between the cardiac glycoside‐induced senescent cell morphology and Rho/Rho kinase pathway
  1094. The correlation between the decline of the positive inotropic effect and the loss of cardiac glycosides from isolated atria during wash-out
  1095. The correlation of cardiac glycoside subcellular distribution with pharmacological effect in the isolated perfused guinea pig heart
  1096. The current concept for the cardiac glycoside receptor
  1097. The Current Concept on Mechanism of Positive Inotropic Action of cardiac glycosides on the Heart
  1098. The current concepts of the effect of cardiac glycosides on sinus node function and atrioventricular conductivity
  1099. The cytotoxic activities of cardiac glycosides from Streptocaulon juventas and the structure–activity relationships
  1100. The Diabetic Heart and cardiac glycosides
  1101. THE DURATION OF ACTION OF SOME cardiac glycosides AND AGLYCONES IN THE GUINEA‐PIG
  1102. The effect of beta-receptor blockers and cardiac glycosides on the heart rate, systolic blood pressure and ST interval in submaximal ergometer exertion
  1103. The effect of cardiac glycoside on microphonic potential
  1104. The effect of cardiac glycosides and electrolytes on cell membrane sodium, potassium-adenosine triphosphatase
  1105. The effect of cardiac glycosides on the heart block produced in the guinea-pig by adenosine and its derivatives.
  1106. The effect of cardiac glycosides on the Na+ pump current‐voltage relationship of isolated rat and guinea‐pig heart cells.
  1107. THE EFFECT OF cardiac glycosides ON THE POLYMERISATION OF CARDIAC ACTIN
  1108. The effect of cardiac glycosides on the respiration of cardiac muscle
  1109. THE EFFECT OF cardiac glycosides ON THE VENTRICULAR FIBRILLATION THRESHOLD IN THE ISCHEMIC AND NON-ISCHEMIC DOG HEART
  1110. The effect of cardiac glycosides on the visual system of man measured with cortical evoked potentials
  1111. The Effect of Disease on cardiac glycoside Pharmacokinetics
  1112. The Effect of Myocardial Contraction on the Uptake and Retention of a Tritium-Labelled cardiac glycoside
  1113. The effect of probenecid on the in vitro absorption of cardiac glycosides
  1114. The effect of three bufadienolide cardiac glycosides on contraction of isolated rat jejunum
  1115. The effects of a cardiac glycoside on subcellular structures within nerve cells and their processes in sympathetic ganglia and skeletal muscle
  1116. The effects of cardiac glycosides and their interaction with catecholamines on glycolysis and glycogenolysis in skeletal muscle
  1117. The effects of certain physical factors and of the cardiac glycosides on sodium transfer by mouse ascites tumour cells
  1118. The effects of mannitol diuresis on digoxin and phenobarbital handling by the kidney: implications for tubular reabsorption and secretion of the cardiac glycoside.
  1119. The effects of six cardiac glycosides on the transmembrane potential and contractile characteristics of the right ventricle of guinea pigs
  1120. The effects of the cardiac glycosides upon the dynamics of the circulation in congestive heart failure. I. Ouabain
  1121. The electrogenic Na-K pump current and actions of the cardiac glycosides
  1122. The electrogenic sodium pump in guinea‐pig ventricular muscle: inhibition of pump current by cardiac glycosides
  1123. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts
  1124. The estimation of the component cardiac glycosides in digitalis plant samples. II. The estimation of the desgluco-glycosides and some observations on the production …
  1125. The experimental studies on cardiac glycoside (Ouabain) and electrolytes
  1126. The glucosylation of cardiac glycosides in leaves of Convallaria majalis L.
  1127. The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation
  1128. THE HPLC METHOD FOR cardiac glycosides G IN ERYSIMUM CHEIRANTHOIDES AND ITS PREPERATION
  1129. The iDigoxin assay is more sensitive than LOCI digoxin assay for rapid detection of convallatoxin, the active cardiac glycoside of lily of the valley
  1130. The importance of metabolic pathways for the positive inotropic actions of cardiac glycosides and calcium ions
  1131. The in vivo antitumor activity of cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact
  1132. The influence of a-tocopherol-nicotinate (Renascin”) on cardiac glycoside effects
  1133. The Influence of Hypoxia upon the Inotropic Action and the Toxicity of Some cardiac glycosides
  1134. The influence of kidney or liver disorders on the serum concentration and urinary excretion of 3H-peruvoside, a tritium-labelled cardiac glycoside
  1135. The influence of rate of administration upon the lethal dose of cardiac glycosides
  1136. The influence of the cardiac glycoside ouabain on the intraocular pressure and dynamics of the rabbit and the cat
  1137. The influence of the position of attachment of the lactone ring to the steroid nucleus on the action of cardiac glycosides
  1138. The inhibitory effects of cardiac glycosides on 86 Rb uptake of erythrocytes. 3. The influence of different substances on the inhibitory effect of cymarin on 86 Rb-uptake …
  1139. THE INTERACTION OF cardiac glycosides, TETRANDRINE AND Ca~(2+) ON THE GUINEA PIG HEART [J]
  1140. The interaction of the Ca2 (+)-channel blocker verapamil with cardiac glycosides in the rat kidney
  1141. The interaction of the converting-enzyme inhibitor captopril with cardiac glycosides in the rat kidney
  1142. The kinetics of cardiac glycoside inhibition of potassium transport in human erythrocytes
  1143. The lead structure in cardiac glycosides is 5 β,14 β-androstane-3 β,14-diol
  1144. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
  1145. THE MEASUREMENT OF cardiac glycoside CONCENTRATIONS
  1146. The metabolites of cardiac glycosides in human urine
  1147. The minimal effective dose of activated charcoal in the treatment of sheep poisoned with the cardiac glycoside containing plant Moraea polystachya (Thunb) KER …
  1148. The molecular mechanism of cardiac glycoside action
  1149. The Moraceae-based dart poisons of South America. cardiac glycosides of Maquira and Naucleopsis species
  1150. The Na+-Ca2+ Exchanger Is Essential for the Action of cardiac glycosides
  1151. THE NEGATIVE INOTROPIC EFFECT OF INHALATION ANESTHETICS AND COMPENSATION OF THIS EFFECT BY cardiac glycosides
  1152. The neurotoxic effects of prenatal cardiac glycoside exposure: a hypothesis
  1153. The past and present of cardiac glycosides. II. Structure, physical and chemical properties. Pharmacodynamics
  1154. The past and the present of cardiac glycosides. III. Pharmacokinetics
  1155. The permeability of the midgut of three insects to cardiac glycosides
  1156. The pharmacological effects of a new semi-synthetic cardiac glycoside, actodigin, on the dog heart: the relationship between Na⁺+ K⁺-ATPase inhibition and …
  1157. THE PHARMACOLOGY OF AFROSIDE B–A NEW cardiac glycoside.
  1158. The pharmacology of cardiac glycosides
  1159. The Pharmacology of the cardiac glycosides
  1160. The place of cardiac glycosides in the treatment of chronic heart failure
  1161. The place of cardiac glycosides in the treatment of chronic heart failure. Part II. Results of small studies
  1162. The place of cardiac glycosides in the treatment of chronic heart failure. Part III. The DIG trial
  1163. The positive inotropic action of cardiac glycosides on cardiac ventricular muscle
  1164. The problem of the cellular receptor for cardiac glycosides (author’s transl)
  1165. The Question of Dosage and Method of Administration of cardiac glycosides in Cases of Cardiac Failure: PANEL DISCUSSION ON OPINIONS OF CARDIOTONIC …
  1166. The rate of uptake of cardiac glycosides into human cultured cells and the effects of chloroquine on it
  1167. The relationship between Na+, K+-ATPase inhibition and cardiac glycoside-induced arrhythmia in dogs
  1168. The relationship of the sugar moieties of the cardiac glycosides to their toxicity on the intact embryonic chick heart
  1169. The role of arterial baroreceptors in mediating the cardiovascular response to a cardiac glycoside in conscious dogs.
  1170. The role of arterial baroreceptors in mediating the cardiovascular response to a cardiac glycoside in conscious dogs.
  1171. The role of cardiac glycosides in influencing breast cancer cell proliferation
  1172. The role of fluorescence polarization immuno-assay in the diagnosis of plant-induced cardiac glycoside poisoning livestock in South Africa
  1173. The role of intracellular Ca ions in the therapeutic and toxic effects of cardiac glycosides and catecholamines.
  1174. The role of intracellular calcium in the positive inotropic and toxic effects of cardiac glycosides in canine Purkinje fibers
  1175. The role of potassium in the inhibition by cardiac glycosides of (Na+-K+)-ATPase prepared from human heart [(proceedings)].
  1176. The sodium pump and hypertension: A physiological role for the cardiac glycoside binding site of the Na, K-ATPase
  1177. The stereoisomers quinine and quinidine exhibit a marked stereoselectivity in the inhibition of hepatobiliary transport of cardiac glycosides
  1178. The stimulatory effect on human erythrocyte rubidium-86 uptake by anti-cardiac-glycoside antibodies.
  1179. The subcellular localization, fate and handling of cardiac glycosides by HeLa cells
  1180. The sugars of the cardiac glycosides
  1181. The time courses of the changes in contractile force and in transmembrane potentials induced by cardiac glycosides in guinea-pig papillary muscle
  1182. The titration of the cardiac glycoside binding site of the (Na++ K+)-adenosine triphosphatase
  1183. The toxic effects on cardiac myocytes of tyledoside F, a cumulative neurotoxic cardiac glycoside isolated from Tylecodon grandiflorus
  1184. The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: discovery of an active cardiac glycoside from Urginea maritima
  1185. The transport of the cardiac glycoside ouabain by the Malpighian tubules of Zonocerus variegatus
  1186. The treatment of Moraea polystacha (Thunb) Ker-Gawl (cardiac glycoside) poisoning in sheep and cattle with activated charcoal and potassium chloride
  1187. The uptake and binding of six radiolabeled cardiac glycosides by guinea-pig hearts and by isolated sarcoplasmic reticulum
  1188. The uptake of cardiac glycosides by intestinal smooth muscle of the guinea-pig in relation to digitalis receptors
  1189. The uptake of cardiac glycosides by rabbit and rat myometrium
  1190. The uptake of cardiac glycosides in relation to their actions in isolated cardiac muscle
  1191. The use of theoretical conformation analysis in the study of the mechanism of interaction of carbohydrate components of cardiac glycosides with receptor
  1192. Therapeutic drug monitoring of anticonvulsivants, cardiac glycosides and theophylline: practical realization and clinical interpretation of the results
  1193. Therapeutic equivalence and inequivalence of chemically identical substances using cardiac glycosides for an example (author’s transpl)
  1194. Therapeutic Potential of cardiac glycosides Against Cancer
  1195. Therapeutic range of cardiac glycosides
  1196. Therapy of paroxysmal atrial fibrillation. cardiac glycosides alone or combined with anti-arrhythmia agents?
  1197. Therapy with cardiac glycosides
  1198. Thermal tranformation of cardiac glycosides
  1199. Thin‐layer chromatography of cardiac glycosides
  1200. Three new cardiac glycosides obtained from the roots of Streblus asper Lour. and their cytotoxic and melanogenesis-inhibitory activities
  1201. Thyroid-induced alterations in myocardial sodium-potassium-activated adenosine triphosphatase, monovalent cation active transport, and cardiac glycoside binding.
  1202. Thyroidal iodide transport I. cardiac glycosides and the role of potassium
  1203. Tissue binding sites involved in quinidine-cardiac glycoside interactions.
  1204. Tissue distribution of cardiac glycosides
  1205. Towards Understanding the Molecular Mechanism of the Inhibitory cardiac glycoside Interaction with the Receptor Enzyme Na+/K+-Transporting ATPase
  1206. Toxicological studies on the latex of the usher plant Calotropis procera (Ait.) in Saudi Arabia. V-seasonal variation of total cardiac glycosides in the usher plant latex …
  1207. Toxicological study of the different organs of Corchorus olitorius L. plant with special reference to their cardiac glycosides content
  1208. Transcriptome and Metabolite analysis reveal candidate genes of the cardiac glycoside biosynthetic pathway from Calotropis procera
  1209. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco‐2) cells
  1210. Transport and Storage of cardiac glycosides in Organ Cultures and Plants of Digitalis lanata
  1211. Transvaalin, a cardiac glycoside isolated from Urginea burkei, Bkr.(Transvaal Slangkop)
  1212. Trial watch: cardiac glycosides and cancer therapy
  1213. Two cases of cardiac glycoside poisoning from accidental foxglove ingestion
  1214. Two new cardiac glycosides, Rubellin and Transvaalin, from South African species of Urginea
  1215. Two Novel Types of cardiac glycosides from Parepigynum funingense and the Possible Biogenesis
  1216. Two receptors for cardiac glycosides in the heart
  1217. TXA9, a cardiac glycoside from Streptocaulon juventas, exerts a potent anti-tumor activity against human non-small cell lung cancer cells in vitro and in vivo
  1218. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells
  1219. Uptake and sequestration of ouabain and other cardiac glycosides inDanaus plexippus (Lepidoptera: Danaidae): Evidence for a carrier-mediated process
  1220. Uraemic and normal plasma protein binding of various cardiac glycosides under “in vivo” conditions
  1221. Use of cardiac glycosides and risk of glioma
  1222. Use of cardiac glycosides for treatment of cancer: Determinants of cancer cell sensitivity
  1223. Use of cardiac glycosides in chronic circulatory insufficiency
  1224. Use of cardiac glycosides in Finland
  1225. Use of glucagon in cardiac glycoside poisoning in patients with congestive circulatory insufficiency
  1226. Using computer graphics to study cardiac glycoside-receptor interactions
  1227. Using Tissue Culture Techniquefor the Production of cardiac glycosides From Roots of Digitalis purpurea L Plantlets (Var. Excelsior Mixed)
  1228. Utilization of cardiac glycosides in Czechoslovakia–does it correspond to need?
  1229. Vagal role in potentiation by Ca2+ ions of the action of cardiac glycosides on the atrial specialised tissue.
  1230. Variation in cardiac glycoside content of monarch butterflies from natural populations in eastern North America
  1231. Variation in sensitivity of the cardiac glycoside receptor characteristics of (Na++ K+)-ATPase to lipolysis and temperature.
  1232. Zebrafish chemical screening reveals the impairment of dopaminergic neuronal survival by cardiac glycosides
  1233. α2‐Adrenoceptor blockade prevents cardiac glycoside‐evoked neurotransmitter release from sympathetic nerves in dog saphenous vein
  1234. Δ5-3β-Hydroxysteroid dehydrogenase/Δ5-Δ4-ketosteroid isomerase (3β-HSD), a possible enzyme of cardiac glycoside biosynthesis, in cell cultures and plants of …
  1235. Δ5-3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4-Ketosteroid Isomerase (3β-HSD), an Enzyme of cardiac glycoside Biosynthesis, in Cell Cultures of Digitalis lanata
Related Posts

BH3 MIMETICS

Ameliorates Memory Impairment

Calorie Restriction & Lifespan Extension

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping